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SUMMARY
Appearance of hepatic foci in the pancreas has been described in animal 
experiments and in human pathology. This work presents evidence to show that 
pancreatic cells can be converted into hepatocytes by glucocorticoid treatment. This 
occurs both in a pancreatic cell line, AR42J-B13, and in organ cultures of pancreatic 
buds from mouse embryos. The results demonstrate that metaplasia can be caused by a 
change to the environment of the cells and need not involve somatic mutation.
Using the AR42J-B13 cells we have established several features of the 
mechanism of the transdifferentiation: (1) a proportion of the hepatocytes arise directly 
from differentiated exocrine cells. This is shown by incorporating a GFP gene driven 
by the elastase promoter into the AR42J cells. Although the elastase promoter is 
switched off during the transformation some of the cells remain transiently green due 
to perdurance of the GFP. (2) Many of the hepatocytes are formed with no intervening 
cell division, shown by a failure to incorporate BrdU over the period of the 
transformation. (3) The molecular events associated with the transformation are 
induction of C/EBPP followed by the nuclear translocation of HNF4aand the 
activation of differentiated hepatic products. Transfection of C/EBPp into the cells can 
itself provoke the transdifferentiation while LIP (liver inhibitory protein), the 
dominant-negative form of C/EBPP can inhibit the process, suggesting that C/EBPp is 
a key component distinguishing between the liver and pancreatic programs of 
differentiation. (4) Epithelial morphogenesis plays an important role in hepatic 
transdifferentiation of pancreas: addition of cytochalasin D, an inhibitor of actin 
polymerisation, can prevent epithelial morphogenesis and liver gene expression.
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1.1 Definition of metaplasia
Metaplasia is the name used to describe the conversion in postnatal life of one 
tissue type to another (Slack, 1986; Okada 1991). This term was introduced following 
anatomical and histological observation of the unexpected appearance of foreign 
tissues in ectopic sites. Therefore, “metaplasia” in some cases may be due to selective 
outgrowth of the minor cell types originally contained in a given organ. In other cases, 
metaplasia may be brought about by the differentiation of unspecific stem cells, or by a 
switch of pre-existing differentiated cells. Only the last categories should be counted 
as true metaplasia. In order to distinguish this case from overgrowth of one cell type 
by another, a term “cellular metaplasia” is often used.
Another term, transdifferentiation, was first introduced to denote a switch in cell 
differentiation by Selman and Kafatos (Selman et al., 1974). They observed a cell 
switch occurred normally in insect development. Okada and Eguchi identified the 
switch of pigment cells to lens as “transdifferentiation”, which was convincingly 
demonstrated through in vitro clonal cell culture (Eguchi 1975; Araki and Okada, 
1977). Based on their definition, transdifferentiation is an irreversible switch of one 
type of differentiated cell to another type of normal differentiated cell. There are two 
important criteria that need to be established: (1) The differentiated states before and 
after the transdifferentiation must be clearly defined which requires both 
morphological and molecular characterization; (2) The cell lineage relationship 
between the two cell types needs to be established.
Cellular metaplasia (or transdifferentiation) can be defined simply as a switch (or 
reprogramming) of cells, which have already expressed specific differentiated traits 
into another cell type distinguished from the original cells, by a set of phenotypic
characters. The wider class of metaplasias also includes cases in which stem cells of 
one tissue type switch to become those of another (Slack and Tosh, 2001).
1.2 Introduction to metaplasia -  importance in development and disease
Metaplasia is always found in association with tissue damage and regeneration. It 
happens because there are errors leading to the cells changing their state of 
developmental commitment. Metaplasia in epithelia are common and do in fact often 
consist of a conversion of a patch of tissue into another type that arose as an adjacent 
rudiment in the embryo (Table 1.1, Slack 1985). For example, patches of ectopic 
intestinal epithelium are found in the stomach (Matsukura et al., 1980) or colonic type 
epithelium in the urinary bladder (Ward 1971).
During embryogenesis, tissues that develop as neighbouring rudiments in a 
common cell sheet will have similar combinations of transcription factors defining 
their commitment and may differ by the expression of just one gene. A previous 
theoretical work suggested that metaplasias might result from somatic mutation of 
homeotic genes normally required to distinguish tissue rudiments from one another 
(Slack 1985). Assuming that cells are indeed the same as the original embryonic 
progenitors for the tissue, then a change of state of such a gene in later life would 
cause the cells to “flip” from producing one tissue to producing another (Fig. 1.1; 
Slack 2000: Slack and Tosh, 2001).
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Table 1.1 List of examples of epithelial metaplasia 
(Table adapted from Slack, 1986)
Ectopic tissue Location Condition
Intestine Stomach Intestinal Metaplasia in a atrophic
gastritis
Gastric (body type) Duodenum and jejunum Gastric metaplasia in duodenitis
Intestine (colonic) Urinary bladder Cystitis glandularis from Brunn’s
nests
Endocervical Ovary Mucinous cystadenoma
Tubal Ovary Serous cystadenoma
















Gene X on Gene X off
Type A Tissue
Transdifferentiation occurs
Fig 1.1 Mechanism of transdifferentiation in postnatal life. In the embryo, two tissue 
types arise from a common cell sheet because the master switch gene, X is activated in 
A tissue through induction by a morphogen but not in the other. In a postnatal life, 
either a change in the cellular environment or somatic mutation turns this gene X on in 
one or a few cells of the B tissue, then a metaplasia will result. (The figure was 
modified from Slack 2000)
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For example, the homeobox gene Cdx2, a homologue of the Drosophila gene 
caudal, has been implicated in the control of cell differentiation in the intestinal 
epithelium. Recently, Fumess and colleagues have shown that mice in which one allele 
of the Cdx2 gene had been inactivated by homologous recombination developed 
multiple intestinal polyp-like lesions in the colon (Beck et al., 1999). These lesions that 
didn’t express Cdx2 were composed of heterotopic oesophageal-type epithelium 
together with some stomach and small intestinal mucosa. The result suggests Cdx2 
directs endodermal differentiation toward a caudal phenotype. The haploinsufficient 
levels of expression in the developing distal intestine leads to metaplasia to a more 
rostral endodermal phenotype, such as forestomach epithelium that does not express 
Cdx2 during normal development
Since metaplasia represents a switch in developmental commitment of one tissue 
type to another, investigating metaplasia provides a novel opportunity to explore the 
cellular and molecular mechanisms underlying specification of different organs during 
the development.
1.3 Hepatic metaplasia of the pancreas
The appearance of hepatic foci in the pancreas occurs in rats, hamsters, mice, 
monkey and human in various conditions (Table 1.2). For example copper depletion 
of the diet (Rao et al., 1986c), or following transplantation (Dabeva et al., 1997), or in 
transgenic mice overexpressing Keratinocyte Growth Factor in the pancreas 
(Krakowski et al., 1999). It has also been observed naturally in the vervet monkey 
(Wolfe-Coote et al., 1996) and in human pancreatic tumours (Paner 2000). Although 
these whole organism observations cannot prove definitively that the hepatocytes
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derive from pancreatic cells, they do suggest the likelihood of a relatively high 
frequency conversion between pancreatic cells and hepatocytes. Pancreatic-type tissue 
has also been found to occur in the livers of rats treated with polychlorinated biphenyls 
(Rao et al., 1986a), in fish liver tumors induced by chemical carcinogens, or in the 
liver of a human patient with hepatic cirrhosis (Wolf et al., 1990). The interconversion 
between pancreas and liver may reflect the close developmental relationship between 
the two tissues.
Liver and pancreas both originate from the foregut endoderm (Zaret, 1998; Slack, 
1995). Although recently FGFs have been suggested to be implicated in the 
specification of liver development (Jung et al., 1999), the mechanism regulating 
endodermal epithelium to develop into pancreas and liver remains unclear. 
Presumably, there might be a gene(s) which distinguishes these two tissues in normal 
development. Under certain conditions, a discrete change in the expression of this 
gene might cause the hepatic metaplasia of pancreas in postnatal life. As a result, the 
system of hepatic metaplasia of pancreas provides a novel opportunity to elucidate the 
cellular and molecular mechanisms that control the development of two important 
endodermal organs-liver and pancreas.
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Table 1.2 Examples of hepatic metaplasia in the pancreas
Species Condition or Treatment References
Hamster Single dose of NBOP in regenerating Scarpelli and Raol981
pancreas.
Rat Fed with Ciprofibrate Reddy et al., 1984
Rat Copper-depletion-repletion. Rao et al., 1986c; Rao
et al., 1988
Monkey Partial obstruction of main duct by Wolfe-Coote 1996
cellophane wrapping.
Mice KGF (FGF-7) transgenic mice (driven Krakowski 1999
by Insulin promoter)
Human Malignant islet tumour Paner 2000
Human Ductal carcinoma Paner 2000
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One of first animal models to describe that pancreatic cells can be converted into 
hepatocytes was performed by Rao and colleagues (Scarpelli and Rao, 1981). While 
they were trying to use a methionine-deficient protocol to induce regeneration of 
pancreas in Syrian golden hamster, they found that regenerating pancreatic cells were 
converted into hepatocyte-like cells, as judged by the presence of albumin, 
peroxisomes, and a variety of morphological features. These cells are stable after the 
conversion has been triggered by a single dose of the carcinogen Af-nitrosobis (2- 
oxopropyl) amine administered during the S phase in regenerating pancreatic cells. 
This suggests that, given the proper stimulus, regenerating cells in adult pancreas can 
be redirected into a totally different pathway of differentiation to hepatocytes.
Treatment of rodents with peroxisome proliferators (e.g. Ciprofibrate) (Rao et al., 
1982; Reddy et al., 1984), certain carcinogens (Rao et al., 1988b; Monis et al., 1991; 
Waalkes et al., 1992), or copper depletion followed by copper repletion (Rao et al., 
1986c; Rao et al., 1988a; Dabeva et al., 1995) can generate hepatocytes in the 
pancreas. The most extensively studied in vivo model of the hepatic metaplasia of 
pancreas is the copper depletion-repletion protocol (Rao et al., 1988a). This is a highly 
reproducible in vivo model, in which hepatocytes were induced in the pancreas of adult 
rats that were maintained on copper-deficient diet containing a relatively non-toxic 
copper-chelating agent, Trien (triethylenetetramine tetrahydrochloride)(0.6% w/w) for 
7-9 weeks and then returned to normal rat chow. Alternative Cu chelates (e.g. D- 
penicillamine) have been used, but those proved to be more toxic. The copper 
depletion results in almost complete loss of pancreatic acinar cells at the end of 
copper- depletion regimen, and in the development of multiple foci of hepatocytes 
during the recovery phase. In some animals, liver cells occupied more than 60% of
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pancreatic volume within 6-8 weeks of recovery (Rao et al., 1988a).
It is believed that copper deficiency in rats leads to global acinar cell loss due to 
apoptosis. It possibly causes perturbations in cell-cell interactions and the 
microenvironment (Rao et al., 1993). Loss of acinar cells was associated with the 
proliferation of ductular epithelial and oval-like cells (similar to the oval cells in the 
liver- the progenitors of the liver stem cell). Massive depletion of the acinar cell pool 
creates severe expansion pressure on oval and ductular cells to fill the vacuity (Rao et 
al., 1989). This probably causes a change in the commitment of these cells resulting in 
transdifferentiation into hepatocytes (Rao and Reddy, 1995).
1.4 Origin of pancreatic hepatocytes
The pancreas is an organ containing exocrine and endocrine tissues. The exocrine 
tissue is composed of the acinar cells secreting the digestive enzymes (e.g. amylase, 
lipase, and elastase) together with the epithelial cells of the pancreatic ducts which 
transport the digestive enzymes from the pancreas to the small intestine. These ducts 
may perhaps be the site of residence of pancreatic stem cells responsible for renewing 
the tissue (Ramiya et al., 2000). The endocrine cells are mostly organised into the 
islets of Langerhans and are subdivided into different cell types depending on the 
hormone that they secret (a  cells: glucagon, P cells: insulin, 5 cells: somatostatin, PP 
cells: pancreatic polypeptide). The question arises here if hepatocytes arise from 
differentiated pancreatic cells, then which type of pancreatic cells is the cell of origin? 
The whole animal experiments have suggested several different answers to this 
question.
Ciprofibrate, a peroxisome proliferator, can induce hepatocytes in the pancreas of 
adult male F-344 rats when added to their diet at a dosage of 10 mg/kg body weight for
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60-72 weeks (Reddy et al., 1984). These cells are morphologically indistinguishable 
from hepatic hepatocytes and were usually localized adjacent to islets of Langerhans 
with extensions into surrounding acinar tissue. A significant increase in the volume 
density of peroxisomes, together with immunochemically detectable amounts of two 
peroxisome-associated enzymes, was observed in pancreas of rats maintained on 
ciprofibrate. Uricase-containing crystalloid nucleoids which are specific for rat 
hepatocyte peroxisomes were present. These structures facilitated the identification of 
cells with hybrid cytoplasmic features characteristic of both pancreatic acinar or 
endocrine cells and hepatocytes. These cells are presumed to represent a transitional 
state in which pancreas-specific genes are being repressed while liver-specific ones are 
simultaneously expressed. The presence of exocrine and/or endocrine secretory 
granules in such transitional cells indicates that acinar or endocrine cells represent the 
precursor cell from which pancreatic hepatocytes are derived.
Another suggestion is that pancreatic ductular epithelium in the hamster is the cell 
of origin (Makino et al., 1990). In the copper depletion-repletion rats, during the 
depletion period, there was an increase in the number of adipocytes in the interstitium, 
and in the number of interstitial and ductular cells. After 7 weeks of copper 
deficiency, albumin mRNA is localized over interstitial and ductular cells. These cells 
resemble morphologically the epithelial progenitors of the liver (Rao et al., 1989; 
Dabeva et al., 1995).
Finally, in a recent study, Krakowski generated transgenic mice in which KGF 
was driven by the insulin promoter (Krakowski et al., 1999). Remarkably, they found 
that ectopic KGF expression resulted in the emergence of hepatocytes within the islets 
of Langerhans in the pancreas. Additionally, significant intra-islet duct cell 
proliferation in the pancreas of transgenic KGF mice was observed. The unexpected
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appearance of hepatocytes and proliferation of intra-islet duct cells in the pancreas of 
these mice might suggest endocrine cells have the potential to transdifferentiate into 
hepatocytes upon local exposure to KGF.
So these three studies have each suggested a different cell of origin for the 
pancreatic hepatocytes: acinar, endocrine or ductular. However, it is difficult from the 
whole-animal experiments to establish conclusively the progenitor cell type of the 
hepatocytes because no labelling of individual cell lineages could be carried out.
1.5 Molecular basis of hepatic metaplasia of pancreas
Fibroblast growth factors and several families of transcription factors including 
hepatocyte nuclear factors (HNF) 1, 3 and 4 and CCAAT/enhancer binding proteins 
(C/EBP) have been shown to be important components of the differentiation process 
that culminates in the fully functional liver (Darlington 1999). It is not clear whether 
these factors are involved in the generation of hepatic metaplasia. So far, only Dabeva 
and Rao have tried to determine the mechanism using northern blotting. The results 
show the pancreatic ductular cells express HNF-1, HNF-3a, HNF-3p, HNF-4, 
C/EBPa, C/EBPp, and C/EBP5 (Dabeva et al., 1995; Rio et al., 1996) which suggest 
these liver-enriched transcription factors (LETFs) may be involved in the mechanism 
underlying the process of metaplasia. However some of these transcription factors 
were also found to be present in the pancreas and other tissues (Cereghini, 1996). For 
example, the mRNA of HNF-4 and HNF-1 increased after 5 weeks copper depletion in 
those pancreatic epithelial progenitors, but HNF-4 and HNF-1 are also found to be 
expressed in the islet of Langerhans (Miquerol et al., 1994), especially HNF-1 is 
essential for insulin gene transcription (Emens et al., 1992; Wang et al., 1998).
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If these transcription factors also regulate pancreatic phenotype, then the results do 
not provide us with a clear molecular mechanism to understand how these factors 
induce the conversion of pancreatic cells to hepatocytes. In order to understand 
whether the process of metaplasia is governed by the combined action of the LETFs, 
we need a model system to further analyse the process. Thus it might be very helpful 
if we can establish an in vitro model for the hepatic metaplasia of the pancreas.
1.6 Objectives of the current work
Numerous examples have been described that indicate hepatic metaplasia of 
pancreas is a reality and can occur in vivo, however very little is known of the 
molecular and cellular mechanisms involved. There are four questions that arise. 
Firstly, we would like to ask whether or not hepatic metaplasia is a true example of 
transdifferentiation? If so, it needs to fulfill the two important experimental criteria 
defined by Eguchi and Kodama- (1) The two differentiated states before and after the 
transdifferentiation must be clearly defined, which will require both morphological and 
molecular characterisation. (2) The cell lineage relationship between the two cell types 
needs to be established, usually using a tissue culture system. Secondly, are cell type 
transformations the result of somatic mutations or of the environmental 
reprogramming of cells? Thirdly, if this is not the case of metaplasia, do all such 
changes represent transformations between stem cells? Fourthly, what are the genes 
whose altered expression underlies the changes?
Using a suitable in vitro model will help to address these four questions. In the 
present study, I have firstly established an in vitro model, and used the model to 
establish morphological and molecular characterisation of the transdifferentiation 
process. Secondly, I have investigated the cell linage relationship to determine the
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origin of the pancreatic hepatocytes. Thirdly, I have attempted to define each phase of 
the pathway leading to the conversion and determine whether somatic mutations or 
environment caused the transformation. Fourthly, I have determined the expression 





2.1 Cell lines and Culture Conditions
AR42J is a rat pancreatic exocrine cell line purchased from ECACC (European 
Collection of Cell Cultures, Proton Down, U.K.). AR42J-B13 cell (kindly provide by 
Dr. I. Kojima, Tokyo, Japan) is a subclone of the parent line AR42J. Both cell lines 
were maintained in Dulbecco’s modified Eagle’s medium (Sigma, Poole, U.K.) 
containing 2 mM L-glutamine, 0.5 u/ml penicillin, 500ng/ml streptomycin, and 10% 
fetal bovine serum (Life Technologies, Glasgow, U.K.). The medium was renewal 
every 2- 3 days, and subculture was performed every 4-6 days at a ratio of 1:7-1:10. 
Cells were frozen in fetal bovine serum containing 10% DMSO, and kept in liquid 
nitrogen or at -80°C.
RIN-5F cell line, a subclone of the RIN-m rat islet cell line, was purchased 
from ECACC (European collection of cell cultures). Cells were maintained in RPMI 
1640 medium (Sigma, Poole, U.K) containing 2 mM L-glutamine, 0.5 u/ml penicillin, 
500ng/ml streptomycin, and 10% fetal bovine serum. The medium was renewed every 
2-3 days. Subculture was performed every 6-8 days at a ratio of 1:3-1:5. Cells were 
frozen and stored in fetal bovine serum containing 10% DMSO, and kept in liquid 
nitrogen or at -80°C.
Dexamethasone (Dex) was added at InM-ImM as a solution in ethanol and 
medium changed every 2-3 days (control cells received ethanol alone). RU486 
(BIOMOL, Plymouth, U.S.A) was added at 2.5 pM concentrations, the treatment 
commencing 1 hour before addition of the Dexamethasone. In some experiments, 
Hepatocyte growth factor (R&D system, Oxon, U.K.) or Oncostatin M (R&D system, 
Oxon, U.K.) was added as a solution in phosphate-buffered saline contained 0.1% 
bovine serum albumin at a final concentration of 100 pM or 10 ng/ml together with 
or without 1 pM Dex.
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For the stability determination- AR42J-B13 cells were treated for 2 weeks with 
1 jiM Dex, then split and cultured with 1 pM Dex and 10 ng/ml OSM for a forther 4 
days. Cells were then cultured in control medium without Dex, fixed after 4 days and 
10 days. Secondly, AR42J-B13 cells were treated for 4 weeks with Dex, large cells 
(>2 fold) were then sorted by cell sorter. After cells were recovered, some clones were 
picked and then cultured with 1 pM Dex for a further 4-6 weeks. After splitting, cells 
were cultured with 1 pM Dex for a further 4 days, then Dex was removed from 
medium and cells were fixed after 14 days.
Cell growth was analysed by seeding 1x10s cells in 35 mm dishes with or 
without Dex. Cells were trypsinised and subsequently counted in a haemocytometer.
2.2 Embryonic culture of mouse pancreatic buds
Cultures were set up as described in Percival and Slack (1999) with minor 
modification. Briefly the dorsal buds were isolated from El 1.5 mouse embryos. To set 
up cultures, the coverslips were placed in 35 mm petri plates containing BME medium 
with Earle’s salts, 20% fetal bovine serum and 50 p.g/ml gentamycin (all were 
purchased from Life Technologies, Glasgow, U.K.). A stainless steel cloning ring of 3 
mm internal diameter was placed over the fibronectin-coated area, and the pancreatic 
bud was dropped into the center. To ensure spreading during culture, the buds were 
turned if necessary with a fine needle so that the cut surface lay in contact with 
fibronectin. Cultures were maintained for up to 7 days at 37°C in 5% C 0 2, with a 
change of medium everyday. The stainless steel ring was removed at the second day of 
culture.
Treatment with Dexamethasone was started after 48hrs in culture. The medium 
was changed each day with addition of Dex. All trans-retinoic acid (Sigma, Poole,
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U.K.) was reconstituted in DMSO at lOmM and used at 0.1, 1 or 10 pM with or 
without 1 |iM Dexamethasone. The medium was change daily with or with retinoic 
acid.
2.3 Immunofluorescence Analysis
For immunofluorescent staining, cells were cultured on noncoated glass 
coverslips, rinsed with PBS, fixed with 4% paraformaldehyde (PFA) in PBS for 30 
min or ice cold Acetone/Methanol (1:1) solution for 5 min. For PFA fixed cells, cells 
were then permeabilised with 0.1% (vol/vol) Triton X-100 in PBS for 30 min, and 
incubated in 2% blocking buffer (Roche, East Sussex, U.K.) which contained 0.1% 
Triton X-100, then incubated sequentially with primary antibodies for overnight at 4°C 
and secondary antibodies for 3 hrs at room temperature. After incubation of secondary 
antibodies, cells were washed 3 times with PBS buffer, and then mounted in Gelvatol 
medium (prepared by dissolving 20g of polyvinyl alcohol, in 80mls of lOmM Tris [pH 
8.6], and 3g of n-propyl gallate in 50mls glycerol followed by mixing and 
centrifugation at 7000 g to remove any undissolved particles). Alternatively, for 
staining of pancreatic bud cultures, the pancreatic buds were fixed in MEMFA (10% 
formaldehyde, 0.1M Mops, pH 7.4, EGTA 2mM, MgSC>4 ImM) for 30-45 min at room 
temperature. They were then washed in PBS and stored in PBS at 4°C for up to a few 
days. Prior to immunostaining, the cultures were treated with 1% TX100 in PBS and 
then blocked as above. The details and working dilution of antibodies has been listed 
in Table 2.1 and Table 2.2
Specimens were observed either using a Zeiss confocal microscope (LSM510) 
or with a Nikon fluorescent microscope. Image collection from the Nikon was made
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with a Hamamatsu C4880 cooled CCD camera and the images processed with Image 
Pro Plus and Photoshop.
G6Pase or albumin positive cells were counted on the basis of 
immunocytochemistry. Images were collected under the same conditions from at 
least five different regions of Dex treated cells by using the Zeiss LSM510 confocal 
microscope. The number of positive cells were counted manually, and the total 
numbers for each specimen are larger than 500. Values are the means±SD for 3 
experiments.
For staining of mitochondria, cells were loaded with 1 pM Rhodamine 123 
(Molecular probe, Leiden, Netherlands) for 10 min at room temperature, and then 
fluorescent signals were observed using a Zeiss confocal microscope (LSM510).
For staining of polymeric forms of actin, phalloidin-FITC (5 jig/ml) or 
phalloidin-TRITC (10 p,g/ml) (both were purchased from Sigma, and dissolved in 
DMSO) were added to specimens 1 hr before mounting in the slides.
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Table 2.1 Working dilution of primary antibodies
Antibody Species Supplier Dilution
oil -antitrypsin Rabbit Polyclonal Sigma 1:400
a-Fetoprotein Rabbit Polyclonal Biomeda 1:300
Albumin Rabbit Polyclonal Sigma 1:500
Albumin Goat Polyclonal Sigma 1:300
Amylase Rabbit Polyclonal Sigma 1:300
BrdU Mouse Monoclonal Sigma 1:200
E-cadherin Mouse Monoclonal Transduction 1:200
P-catenin Mouse Monoclonal Transduction 1:400
C/EBPp Mouse Monoclonal Santa Cruz 1:150
C/EBPp Rabbit Polyclonal Santa Cruz 1:500
Pan-cytokeratin Mouse Monoclonal Sigma 1:400
CK8 Mouse Monoclonal Birgit Lane undiluted
G6Pase Sheep Polyclonal Ann Burchell 1:500
GSK3p Mouse Monoclonal BD 1:200
Glucagon Mouse Monoclonal Sigma 1:100
GR Rabbit Polyclonal Santa Cruz 1:100
GFP Mouse Monoclonal Clontech 1:300
HNF-4a Goat Polyclonal Santa Cruz 1:150
Insulin Guinea-pig Polyclonal Sigma 1:300
IPF-1 (PDX-1) Rabbit Polyclonal Jonathan Slack 1:100
MDR Goat Polyclonal Santa Cruz 1:100
ST (DHEA) Rabbit Polyclonal Mike Coughtrie 1:500
ST (Phenol) Rabbit Polyclonal Mike Coughtrie 1:1000
Transferrin Rabbit Polyclonal Dako 1:200
TTR (Prealbumin) Rabbit Polyclonal Dako 1:100
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Table 2.2 Working dilution of secondary antibodies
Antibody Species Supplier Dilution
Anti-goat IgG FITC Rabbit Polyclonal Sigma 1 300
Anti-goat/sheep IgG FITC Mouse Monoclonal Sigma 1 50/1:150
Anti-guinea-pig IgG TRITC Rabbit Polyclonal Sigma 1 500
Anti-rabbit IgG biotinylated Swine Polyclonal Dako 1 300
Anti-rabbit IgG TRITC Swine Polyclonal Dako 1 200
Anti-rabbit IgG FITC Goat Polyclonal Jackson 1 300
Anti-mouse IgG FITC Horse Polyclonal Vector 1 150
Anti-mouse IgG AMCA Horse Polyclonal Vector 1 100
Anti-mouse IgG Texas Red Horse Polyclonal Vector 1 150
Anti-mouse IgG biotinylated Horse Polyclonal Vector 1 300
Anti-goat IgG biotinylated Horse Polyclonal Vector 1 300
Anti-Sheep IgG Texas Red Rabbit Polyclonal Vector 1 150
Anti-Rabbite IgG FITC Goat Polyclonal Vector 1 200
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2.4 BrdJJ incorporation
Bromo-2-deoxyuridine (BrdU) was purchased from (Sigma, Poole, U.K.). 
BrdU was added as a solution in water at a concentration of 10 pM. Dex was 
added overnight before BrdU was added, and medium containing fresh BrdU and 
Dex was changed thereafter every 2 days. Cells were fixed with 4% 
paraformaldehyde in PBS for 30 min, and then treated with 2N HC1 for 20 min at 
37°C in a water bath. Immunostaining was performed as described above.
2.5 Transfection and production of stable transfectants
The elastase promoter was a gift from Dr. Calvin Swift (Southwestern Medical 
School, Texas), The transthyretin promoter was provided by Dr. R. Costa (University 
of Chicago, Illinois). Both pcDNA3-Elas-GFP2 and pcDNA3-TTR-GFP2 were 
constructed by removing the CMV promoter from the pcDNA3-GFP2 and replaced 
with either the elastase promoter or transthyretin promoter. (Constructs were made by 
Dr. D. Tosh).
Stable transfectants of AR42J-B13 were generated with pcDNA3-Elas-GFP2 
by using neomycin resistance. 1 x 106 cells were seeded in 35 mm dishes and grown at 
37°C, 5% C 02 for overnight, then transfected with 1.5 pg of DNA/dish using FuGENE 
6 transfection reagent (Roche, East Sussex, U.K.) according to the manufacturer’s 
instruction. Stable transfectants were selected in medium containing 800 pg/ml G418 
(Life Technologies, Glasgow, U.K.). After 4 weeks, clones were individually picked, 
then expanded and maintained in medium containing 200 pg/ml G418.
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Transient transfection was also carried out using FuGENE 6 Transfection 
Reagent with 2 jig of DNA per dish and incubated at 37°C 5% CO2 for either 72 hrs or 
120 hrs, Cells were then fixed and immunostaining was performed as described above.
For transfection studies using LIP to prevent transdifferentiation, cells were 
transfected with LIP and then treated for 4 days with 1 (iM Dex and 10 ng/ml OSM. 
Alternatively, AR42J-B13 cells were treated with 1 pM Dex for 8 weeks. Cells were 
then trypsinised, resuspend in PBS, and loaded into cell sorter (Becton Dickinson). 
Normal cell size value (SSC) around 400, and the large cells (SSC> 800) were 
collected. Cells were pelleted down, and cultured in medium with 1 pM Dex for two 
weeks. These cells were exposed to 1 pM Dex and 10 ng/ml OSM for 5 days prior to 
transfection with LIP. Following transfection the cells were treated with 1 pM Dex 
and 10 ng/ml OSM for 72hrs.
For transfection studies using TTR-GFP to determine the stability of the 
transdifferentiation, AR42J-B13 cells were treated for 2 weeks with 1 pM Dex, then 
split and cultured with 1 pM Dex and 10 ng/ml OSM for 4 days prior to transfection 
with CMV-nucGFP or TTR-nucGFP followed by exposure to 1 pM Dex and 10 ng/ml 
OSM for a further 72 hrs. Cells were then cultured in control medium without Dex, 
and the dish was photographed each other day with the confocal microscope.
2.6 RT-PCR
Total RNA was extracted using the TRI reagent (Sigma, Poole, U.K.). Briefly, 
cells were seeded on 100mm petri dishes without or with 1 pM Dex treatment for 2d, 
4d, 7d 14d. Cells were lysed directly on the culture dish by adding 1 ml of the TRI 
reagent. After addition of the reagent, the cell lysate was passed several times through 
a pipette to form a homogenous lysate. After homogenization, the homogenate was
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centrifuged at 12,000 x g for 10 minutes at 4°C to remove the insoluble material. The 
clear supernatant was transferred to a fresh tube, and then 0.2 ml of chloroform was 
added to the tube. Covering the sample, it was shaken vigorously for 15 seconds and 
allowed to stand for 2-15 minutes at room temperature. It was then centrifuged at 
12,000 x g for 15 minutes at 4°C. The aqueous phase was transferred to a fresh tube; 
0.5 ml of isopropanol was added and mixed. The sample was allowed to stand for 5- 
10 minutes at room temperature, and then centrifuged at 12,000 g for 10 minutes at 
4°C. The supernatant was removed and the RNA pellet was washed with 75% ethanol. 
The RNA pellet was dried for 5-10 minutes, dissolved in water, and then stored at - 
80°C.
Before carrying out the cDNA synthesis, the RNA samples were digested with 
RQ-1 DNase (Promega, Southampton, UK) to remove any contaminating genomic 
DNA. First strand complementary DNA was synthesized using MMLV reverse 
transcriptase (Life Technologies, Glasgow, U.K.). The primers used are listed in Table 
2.3. The reactions were processed in a DNA thermal cycler in the presence of 1.5 pC
"XO r\of [a- P] dATP under the following conditions: denaturation at 94 C for 1 min, 
annealing at 55°C for 1 min, and extension at 72°C for 1 min. The number o f cycles 
was 27, except for p-actin (22 cycles). The products were separated on a 5% 
polyacrylamide gel, which was dried and exposed to X-ray film. In order to confirm 
the absence of genomic DNA, primers for P-actin span one small intron, so if 
contaminated genomic DNA, and then we will find a 477 bp fragment will be detected.
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TABLE 2.3 Sequences of RT-PCR prim ers
Gene Sense primer Antisense primer Size (bp) Accession
(3-Actin TCCGTAAAGACCTCTATGCC AAAGCCATGCCAAATGTCTC 3 5 3 J 0 0 6 9 1
p48 GCTCCTGGAGCATTTCCCG CTGAGGAACTCTACCTCCGC 2 8 5 X 9 8 4 4 6
HNF-1 CGCATACAAGCCTGCTTCC GAGACGACGGCTCATGAAG 1 4 8 L 0 9 6 4 8
HNF-3a CAGACTCTGGACCACAGTG TTCAGGTGCAGCTGAGATTC 1 6 3 X 5 5 9 5 5
HNF-3J3 GTCAGGAGCACAAGCGAGG TGTGATGATGTTGCTGCTCG 2 4 1 L 0 9 6 4 7
HNF-3y CAAAGAAAGGAAACAGTGCC TTGGAAGGTGTTGATGTCTG 3 0 7 L 0 9 6 4 8
HNF-4 CTCAACTCATCCAACAGCC AAGCACTTCTTGAGCCTGC 2 2 1 D 1 0 5 5 4
HNF-6 GATCAATACCAAAGAGGTGG TTGGACGTCTGTGAAGACC 3 1 6 ( a )  
3 9 4  (P)
X 9 6 5 5 3
Y 1 4 9 3 3
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2.7 Histology and Immunhistochemistry
The pancreas of glucocorticoid treated rats was kindly provided by Prof. J. R. 
Seckl (Dept, of Medical sciences, Western general hospital.), the procedure was 
performed as described previously (Nyirenda et al, 1998). Briefly, mothers were 
treated throughout the 3rd week of gestation (from day 15 to day 21-22 (depending on 
when pups were bom)). The dose of 100 pg/kg (body weight) dexamethasone or 
vehicle was administered subcutaneously each day, and then the rats were sacrificed 3 
weeks postnatally. The pancreas was dissected free, fixed overnight in 4% 
formaldehyde, and embedded in paraffin wax.
Representative sections (7 pm) were stained with haematoxylin and eosin 
(H&E). In addition, serial sections were prepared and immunohistochemically stained 
for insulin or glucagon. Briefly, sections were rehydrated and endogenous peroxidase 
activity was blocked by incubating with 3% H2O2 for 30 min. Sections were then 
blocked for lhr in 2% Roche blocking buffer prior to application of antibodies and 
incubated for 12-14h at 4°C with mouse monoclonal antibody to glucagon (1:300 
dilution) or guinea-pig anti-bovine insulin (1:200 dilution). Biotinylated anti-mouse 
or anti-guinea-pig IgG (Vector Laboratories, Burlingame, U.S.A.) were diluted 1:300 
in PBS and applied for 1 hr. The slides were then washed in PBS and incubated for 
lhr with an ABC kit (Dako, Cambridge, U.K.). Immunoreactivity was localised by 
incubation with DAB (lOmg in 15ml PBS), 0.01% H20 2 for up to 5 min and the 
reaction stopped by washing in PBS. Tissue sections were counterstained with 
haematoxylin.
For immunofluorescence staining on tissue sections, sections were 
permeabilised with 0.1% Triton X-100 in PBS for 1 hr and then blocked for at least 90 
min in Roche blocking buffer. Each primary antibody was applied overnight at 4°C
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and washed the following day three times with PBS, and the secondary antibody was 
applied for 3 hr at room temperature and the slides washed and mounted in Gelvatol 
medium. The details and dilution were decribed in Table 2.1, 2.2
Sections were examined under the Leica DMRB microscope. Images of 
stained specimens were collected with a spot camera drive (Diagnostic Instrument 
Inc.) and stored as 24-bit TIFF images. Pictures of fluorescent specimens were taken 
by using a Zeiss confocal microscope (LSM510).
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CHAPTER 3
IN VITRO CONVERSION OF 
PANCREATIC CELLS INTO HEPATOCYTES
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3.1 Introduction
The conversion of pancreatic cells to hepatocytes is a well-studied example of 
transdifferentiation in mammals. Metaplasia represents a switch in developmental 
commitment of one tissue type to another. Therefore, investigating the metaplasia of 
pancreas to liver provides a novel opportunity to explore the cellular and molecular 
mechanisms underlying the development of these two endodermal organs. Since Rao 
and colleagues first described that regenerating pancreatic cells in hamsters can 
differentiate into hepatocytes (Scarpelli and Rao, 1981). The process of metaplasia of 
pancreas to liver has been investigated for nearly 20 years, but the mechanism which is 
responsible for metaplasia remains unclear. The main reason is that, until recently, no 
reliable in vitro model existed for the hepatic metaplasia of pancreas.
It is believed that one tissue may be replaced by another in two ways: either by 
a switch of developmental commitment or by colonization with cells of different origin 
(Slack, 1986). Only the former is a true metaplasia. Different labs have been using 
various protocols to induce the appearance of hepatocytes in the pancreas (see Chapter 
1; Scarpelli and Rao, 1981; Rao et al., 1982; Reddy et al., 1984; Rao et al., 1988b; 
Monis et al., 1991; Waalkes et al., 1992; Rao et al., 1986c; Rao et al., 1988a; Dabeva 
et al., 1995; Dabeva et al., 1997; Krakowski et al., 1999). If the hepatic metaplasia of 
pancreas is a real example of metaplasia, then two questions arise? First, do all such 
changes represent transformations between stem cells, or can changes also occur 
between actual differentiated cells (i.e. a true transdifferentiation)? Secondly, if 
hepatocytes arise from differentiated pancreatic cells, then which type of the cell is the 
origin of pancreatic hepatocytes? Unfortunately, it is difficult from whole-animal 
experiments to establish conclusively either the progenitor cell type of the hepatocytes 
or the molecular basis of the switch.
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Eguchi and Kodama defined two important experimental criteria that need to 
be established for a process to be defined as transdifferentiation (Eguchi and Kodama 
1993). First, the differentiated states before and after the transdifferentiation must be 
clearly defined, which will require both morphological and molecular characterisation. 
Second, the cell lineage relationship between the two cell types needs to be 
established, usually using a tissue culture system. Our approach to proving or 
demonstrating that pancreatic hepatocytes directly arise from pancreatic cells is to 
establish an in vitro model by using differentiated cell lines. If it proves possible to 
induce metaplastic changes in culture by altering the extracellular environment or by 
gene transfer, then it will be very useful for determining the mechanisms involved. 
The results obtained from animal experiments suggest that hepatocytes might arise 
either from exocrine, endocrine or duct cells (Reddy et al., 1984; Krakowski et al., 
1999; Makino et al., 1990). Therefore, we here tried to use AR42J (rat pancreatic 
exocrine cells), Rin-5F (rat pancreatic (3 cells), and Capan-1 or PANC-1 (human 
pancreatic duct cells) to determine the potential of these cell types to undergo 
metaplasia.
3.2 Hepatic metaplasia in pancreatic AR42J-B13 cells
AR42J cells are derived from azaserine-induced malignant nodules from the rat 
pancreas (Longnecker et al., 1979). These cells possess both exocrine and 
neuroendcrine properties. Because of the short lifetime of dispersed nonimmortalised 
pancreatic acinar cells, this acinar cell line has been and still is a widely used culture 
system (Christophe 1994; Caplin et al., 1999; Harris et al., 1999; Dethloff et al., 2000; 
Thommesen et al; 2000).
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AR42J cells secrete amylase and other digestive enzymes (Christophe, 1994). 
Interestingly, the cells also express neuroendocrine markers such as synaptophysin, 
and neurofilament protein. It can take up and release y-aminobutyric acid (GABA) and 
posses an excitable membrane. When treated with activin A, a member of the TGF-P 
supergene family, AR42J cells extend neurites and express pancreatic polypeptide 
(Yasuda et al., 1994; Mashima et al., 1996a). When the activin A treatment is 
combined with betacellulin or hepatocyte growth factor (HGF), AR42J cells 
differentiate into P cells as determined by expression of insulin and glucose transporter 
2 (GLUT-2) (Mashima et al., 1996a; Mashima et al., 1996b). AR42J-B13, a subclone 
of AR42J cells, are almost entirely converted to insulin-producing cells after the 
incubation with activin A and HGF (Mashima et al., 1996b).
Dexamethasone, a synthetic glucocorticoid, is known to enhance the 
differentiation of AR42J cells toward the exocrine phenotype, increases the number of 
zymogen granules, the level of amylase mRNA, and the secretion of amylase (Logsdon 
et al., 1985). In addition, dexamethasone also shows the ability to induce the synthesis 
of albumin, transferrin, tyrosine aminotransferase, and glucose-6-phosphatase in liver 
cells (Chou et al., 1988; Schmoll et al., 1996; Kamiya et al., 1999). In the present 
study, I initially investigated the effect of dexamethasone (Dex) on AR42J-B13 cells to 
see if Dex causes a similar effect on exocrine expression as the parent cell line-AR42J. 
To our surprise, the results show that the dexamethasone can convert AR42J-B13 cells 
into hepatocyte-like cells. Incubating the cells with lOnM Dex for 5 days increased 
amylase expression in a proportion of cells. However, we observed that some cells 
became larger and flatter. The expression of amylase was also reduced in these cells 
compared to some of their neighbours after 5-days treatment. After 2 weeks, they 
were extremely flattened and the expression of amylase was almost gone (Fig 3.1A-D).
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After a 3 week treatment, they showed strong expression of albumin, a gene known to 
be expressed in liver cells (Fig 3.1E-H). Vehicle controls (ethanol alone) were always 
negative.
AR42J cells treated with dexamethasone grow more slowly than control cells 
(Logsdon et al., 1985). To determine whether the transdifferentiation is paralleled by 
growth arrest, we cultured the cells with different concentrations of Dex (lnM-ljiM). 
(Fig.3.2A). In addition to studying the cell growth, we also stained for albumin 
(Fig.3.2B-F). Concentrations greater than lOnM caused a significant reduction in the 
growth rate from about 6 doublings/week to about 3 doublings/week and this was 
accompanied by changes in morphology (flattened and large), and expression of 
albumin (Fig 3.2A-F).
We found that all effects of Dex were blocked by concurrent treatment of the 
cells with 2.5 pM RU486, the glucocorticoid receptor antagonist (Fig 3.2G). This 
result indicates that the effects are exerted through the glucocorticoid receptor. We 
also tested cortisol, the natural form of glucocorticoid, which showed that it had 
similar effects to Dex (results not shown).
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Fig 3.1 Dexamethasone treatment leads to formation of a flattened, epithelial- 
like, morphology and inhibits the expression of amylase. Albumin expression can be 
seen in some cells. AR42J-13 cells were incubated with 10 nM dexamethasone for 2 
weeks (B-D) or 3 weeks (F-H); (A) Control AR42J-B13 cells were stained for anti­
amylase antibodies, the picture showed the overlaid image of fluorescent (FITC) 
staining and the transmit image. (B-D). After 2 weeks of Dex treatment, cells were 
fixed and stained for anti-amylase antibodies (B). (C). The transmit image of (B). (D). 
The overlay image of (B) and (C). Arrow cells were extremely flattened and the 
expression of amylase was almost gone. (E). Control AR42J-B13 cells were stained for 
anti-albumin antibodies, the picture showed the overlaid image of fluorescent (FITC) 
staining and the transmit image. (F-H). After 3 weeks of Dex treatment, cells were 
fixed and stained for anti-albumine antibodies (F). (G). The transmit image of (F). (H). 
The overlay image of (F) and (G). Some of flat cells strongly expressed albumin, a 
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Fig 3.2 Effect of different concentrations of Dex on the growth rate, morphology 
change and the expression of albumin. (A) Cell growth was analysed by seed lxlO5 
cells in 35mm dishes with different concentrations of Dex (0, 1, 10, 100, 1000 nM). 
Cells were counted after 7 days of Dex treatment. Values are expressed as cell number 
(xlO4) and are means ±SEM of triplicate determinations from an individual 
experiment. (B-F) Cells were incubated without or with dexamethasone (0, 1, 10, 100, 
1000 nM) for 2 weeks, and then fixed and stained for albumin. (G) Every other day, 
RU486 was added at 2.5 pM, the treatment commencing 1 hour before addition of 1 
jliM Dex. After 14-days treatment, cells were fixed and stained for albumin.
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3.3 Characteristics of pancreatic hepatocytes
In order to determine whether these cells express hepatocytic markers, the Dex- 
treated cultures were tested for expression of eight liver-specific markers including 
transferrin (TFN), a  1-antitrypsin (al-AT), transthyretin (TTR), glucose-6-phosphatase 
(G6Pase), and a-fetoprotein (AFP) (Fig 3.3A-E). At least some of the flattened cells 
show expression of all these liver markers. Interestingly, when cultured with 10 nM 
Dex for 6 weeks, some of these cells tended to form bile canaliculi-like structures, and 
P-glycoprotein (MDR) was localised in the membrane surrounding the apical surface 
of hepatocytes (Fig 3.2H). Moreover, we also found phenol sulphotransferase (PST) 
and dehydroepaindrosterone sulphotransferas (DHEAST) were expressed, enzymes 
having a widespread distribution in adult rat livers (Tosh et al., 1996) (Fig.3.3F-G).
The flattened cells were then also examined by using electron microscopy, the 
results also showed typical features of hepatocytes such as extensive endoplasmic 
reticulum, numerous mitochondria and structures resembling bile canaliculi (Shen et 
al., 2000; experiments performed by Dr. Tosh, data not shown). Additionally, to 
determine whether or not mitochondria were functional int these cells containing 
numerous mitochondria, they were loaded with 1 pM Dihydrorhodamine 123 at room 
temperature. After 15 min, the fluorescent signals were only observed in the flattened 




Fig 3.3 Dexamethasone treatment results in the expression of liver markers. Cells 
were incubated with 10 nM dexamethasone for 2 weeks (A-C), 3 weeks (D-E), 6 
weeks (F-H) and stained with (A) transferrin (TFN) (B) ai-antitrypsin (ai-AT) (C) 
transthyretin (TTR) (D) glucose-6-phosphatase (G6Pase) (E) a-fetoprotein (AFP) (F) 
dehydroepaindrosterone sulphotransferas sulphotransferase (DHEA) (G) phenol 
sulphotransferase (PST) (H) P-glycoprotein (MDR).
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Fig 3.4 Mitochondria of flattened cells were stained with Dihydrorhodamine 123. 
AR42J-B13 cells were treated for 4 weeks with Dex, large cells (>2 fold) were 
then sorted by cell sorter. After cells were recovered, some cells were seeded on 
the coverslip, loaded with 1 pM Dihydrorhodamine 123 for 10 min at room 
temperature, and then fluorescent signals (rhodamin) were observed every 5 
minutes by using a Zeiss confocal microscope. (A). Represents the transmit image 
of (B-E). Arrows indicate the flat cells that converted Dihydrorhodamine to 
Rhodamin and showed the red fluorescent staining in (B)-(D).
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The time course of the transdifferentiation process was studied with 1 jjM  Dex. 
The various liver markers appeared in sequence (Fig 3.5). Some cells become 
flattened by 5 days and some of these began to express transferrin and G6Pase. 
Albumin starts to appear from 9 days, only in those cells already expressing G6Pase 
(Fig.3.5; Fig 3.6D). Double staining for amylase and one of the liver markers showed 
that the cells expressing liver markers did not express amylase (Fig. 3.6F-H), although 
a few cells were seen with a faint co-expression, as might be expected if the 
hepatocytes had formerly been exocrine cells.
Because it was expressed in a large number of cells and was one of the earliest 
differentiation markers to appear (see below), we used G6Pase to score several 
experiments. G6Pase is normally found in the (3 cells of the pancreas as well as in 
liver, but no insulin positive cells were found either in the control or in the Dex-treated 
AR42J-B13 cells, so we regard G6Pase as a valid marker for hepatocytes in this series 
of experiments. The proportion of G6Pase positive cells increased to about 25% and 
that of albumin positive cells to about 6% by 2 weeks in 1 |iM Dex (Fig 3.6K).
When cells are stained with two liver markers, the later marker is found only in 
cells expressing the early marker, for example many cells expressing G6Pase also 
express transferrin and many expressing transferrin also express albumin. These results 
suggest the transdifferentiation is a progressive process. Initially, the cells lose the 
pancreatic phenotype, then they start to express some hepatic genes like G6Pase, a- 
fetoprotein, transferrin, and then later they express larger amounts of albumin and 
other gene products characteristic of differentiated hepatocytes (e.g. phenol 
sulphotransferase, P-glycoprotein).
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Hepatic transdifferentiation is also induced by Dex in the parent line-AR42J 
(Fig 3.7). Although we also found the formation of albumin expressing cells in the 
parent cell line AR42J after 2-week treatment, it was at lower frequency than in 







Control Dex 3d Dex 5d Dex 9d Dex 2w
Fig 3.5 Time-course of the transdifferentiation in AR42J-B13 cells treated with 1 |iM 
Dex. Cells were treated for 0, 3, 5, 9, 14 days and then stained for glucose-6- 
phosphatase (A-E), transferrin (F-J) and albumin (K-O).
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Fig 3.6 The transdifferentiation in AR42J-B13 cells treated with 1 |jM Dex. (A-E) 
Cells were treated for 0, 3, 5, 9, 14 days and then dual-immunostained with anti- 
G6Pase (red) and anti-albumin (green). (F-J) Cells were treated with 1 jllM  Dex for 2 
weeks and double label for (F) anti-amylase (red) and anti-albumin (green) (G) anti­
amylase (red) and anti-CK8 (green) (H) anti-amylase (red) and anti-G6Pase (green) (I) 
anti-G6Pase (red) and anti-TFN (green) (J) anti-PST (red) and anti-TFN (green) at 2 
weeks. (K) Time course of appearance of G6Pase and albumin positive cells in 1 pM 
Dex. Error bars are standard deviations.
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AR42j original AR42J-B13
Fig 3.7 Dexamethasone treatments lead to the hepatic transdifferentiation in parent 
cell line AR42J (A) and derivative cell line AR42J-B13 (B). Cells were treated for 
14 days with 1 jiM Dex and then stained for albumin.
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3.4 Origin of pancreatic hepatocytes
Both the parent line AR42J and AR42J-B13 cells are heterogeneous in terms of 
amylase expression. Although no endocrine cells are present in the cultures in the 
absence of activin/HGF treatment, there may well be stem cells present that have the 
potency to produce exocrine, endocrine or hepatocyte-like cells. We only found the 
conversion of the parent line AR42J cells to insulin-producing cells ((Mashima et al., 
1996a; Mashima et al., 1996b) or hepatocyte-like cells was only at low frequency, so 
we attempted to determine whether the hepatocytes might arise either from 
differentiated exocrine cells or from stem cells. In order to distinguish these 
possibilities, we designed a lineage experiment based on the perdurance of green 
fluorescent protein. Wild type GFP protein is more stable than many other proteins and 
can remain in a cell for a number of days after its transcription has been switched off 
and its mRNA has decayed (Corish and Tyler-Smith, 1999). To distinguish exocrine 
from undifferentiated cells, we used the 200bp fragment of the elastase promoter to 
drive GFP (Swift et al, 1989).
We isolated stable transfectants of AR42J-B13 cells containing a nuclear GFP 
gene driven by the elastase promoter. These express GFP in 73% (SD 2.9) of cell 
nuclei under normal culture conditions where the exocrine phenotype predominates. 
When Dex is added, it initially enhances the green fluorescence but over several days 
the proportion of green cells gradually falls. At five days, there are only 29.7% (SD 
7.3) of cells that clearly show green nuclei (Fig 3.8B, 3.9E). Of the cells with flattened 
morphology, associated with the early stages of conversion to hepatocytes, 17.1% (SD
1.7) still have green nuclei (see arrowed cells in Fig 3.8B). 25.1% of cells are found to 
express G6Pase, and of these cells 38.6% contained both GFP and G6Pase (Fig 3.9). 
The persistence of the GFP shows that these nascent hepatocytes must have arisen
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from cells that formerly had an active elastase promoter and therefore were 
differentiated exocrine-like cells. We cannot say that all cells losing GFP expression 
become hepatocytes, nor that all nascent hepatocytes contain residual GFP, but the 
result does clearly show that the direct transdifferentiation from exocrine cells to 
hepatocytes is possible. It is also possible that some of the hepatocytes arise from stem 





Fig3.8 AR42J-B13 cells containing nuclear green fluorescent protein driven by the 
elastase promoter. (A) Dex treatment caused the metaplastic cells to lose the 
activation of the Elastase promoter but GFP protein perdures for days. (B) Elas-GFP 
cells were cultured in medium with 1 |iM Dex, and then the same region of the dish 
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Fig3.9 AR42J-B13 cells containing nuclear green fluorescent protein driven by the 
elastase promoter. Cells were incubated with or without 1 pM Dex for 5 days and 
stained for GFP (green) and (A-B) amylase (red) or (C-D) G6Pase (red). (E). 
Appearance of GFP positive and flattened cells were counted manually. Total 
numbers for each specimen are larger than 500. Values are the means+SD for 3 
experiments. Error bars are standard deviations.
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3.5 Enhancement of the transdifferentiation by combined treatment of Dexamethasone
and Hepatocyte growth factor.
Hepatocyte growth factor (HGF), also known as scatter factor (SF) , was 
originally discovered to play a role in regeneration of the adult liver after partial 
hepatectomy (Michalopoulos and DeFrances, 1997). HGF is also expressed in the 
septum transversum mesenchyme that surrounds the developing liver bud, and c-met, 
the HGF receptor, is expressed on embryonic hepatocytes (Schmidt et al., 1995). 
Homozygous inactivation of either the HGF or c-met genes yields an embryonic lethal 
phenotype between days 13 and 16 of gestation, due to hypoproliferation and apoptosis 
of the hepatic parenchyma (Bladt et al., 1995; Schmidt et al., 1995). These results 
indicate HGF is a key factor for liver growth.
Mashima has shown that HGF not only can induce AR42J-B13 cells to 
transdifferentiate into insulin-producing cells, but it can also reduce the effect of 
dexamethasone on amylase secretion (Mashima et al., 1996b). We tried the combined 
treatment of Dex and HGF to determine if the transdifferentiation of pancreas to liver 
can be enhanced by HGF. The result shows that after 5 days of 1 (iM Dex and lOOpM 
HGF treatment amylase expression is reduced significantly, and more than 25% of 
cells were found to express glucose-6-phosphatase. This result suggests that the 
combination treatment with Dex and HGF can enhance the transdifferentiation 







Fig 3.10 The combined treatment of Dex and HGF enhance the proportion of 
transdifferentiated cells, and pretreatment with RU486 is sufficient to block the 
conversion. Cells were incubated with 1 pM Dex for 5 days without (A, D) or with 
100 pM HGF (B, E). Cells were incubated with 1 jiM Dex for 5 days with the 
pretreatment of 2.5 pM RU486 for 1 hr (C, F). Cells were then stained with anti- 
G6Pase antibodies. (G) Appearance of G6Pase positive cells was counted from 4 
different fields. Total number is >500. Error bars are standard deviations.
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3.6 Almost total conversion of AR42J-B13 cells to hepatocytes by combined treatment 
of Dexamethasone and Oncostatin M
Although the combined treatment of Dex and HGF can enhance the 
transdifferentiation process, there is still a large proportion of cells unchanged. Here, 
we also added Oncostatin M (OSM) to the culture to examine if we can convert most 
cells to hepatocytes in the presence of Dex. Oncostatin M (OSM) is a member of the 
interleukin-6 (IL-6)-related cytokine family that includes IL-6, IL-11, leukemia 
inhibitory factor (LIF), ciliary neurotrophic factor and cardiotrophin-1. These 
cytokines often exhibit similar functions since their receptors utilise gpl30 as a 
common signal transducer (reviewed in Taga and Kishimoto, 1997). Miyajima and 
colleagues provided evidence to demonstrate that OSM, in combination with 
glucocorticoid, can induces maturation of fetal hepatocytes in vitro (Kaymiya et al., 
1999). Furthermore, hematopoietic cells expanding in the fetal liver produce OSM and 
studies of gpl30 knockout mice reveal an essential role for OSM/gpl30 in hepatocyte 
maturation in vivo (Kaymiya et al., 1999).
In particular, two types of human OSM (hOSM) receptors have been identified. 
hOSM shares many biological functions with LIF mediated by the type I receptor 
(Malik et al., 1989), such as induction of differentiation in M l monocytic cells (Rose 
and Bruce, 1991) and of acute phase proteins in hepatocytes (Richards et al., 1992; 
Baumann et al., 1993). In contrast, mouse OSM utilises only its specific receptor-type 
II receptor. As the result, we chose to add human OSM to the culture instead of mouse 
OSM. 10 ng/ml of human OSM was added along with the 1 pM Dex. The result shows 
that after 5 days of 1 pM Dex and 100 pM HGF treatment more than 70% of cells were 
found to express transferrin (Fig 3.11 A-B). The proportion of G6Pase positive cells 
increased to about 89% and that of albumin positive cells to about 64% by 2 weeks in
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1 |xM Dex and 10 ng/ml OSM treated cultures. To compare with 25% and 6% in 1 (iM 
Dex treatment, it suggests that the combination treatment with Dex and OSM can 
cause almost total conversion of AR42J-B13 cells to hepatocytes.
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Fig 3.11 The combined treatment of Dex and OSM convert AR42J-B13 cells to 
hepatocytes. Cells were incubated with 1 pM Dex for 5 days without (A) or with (B) 
10 ng/ml OSM (C-E). Cells were incubated with 1 pM Dex for 14 days without (C) 
or with (D) 10 ng/ml OSM. Cells were then stained with (A-B) anti-transferrin 
antibodies or (C-D) dual-immunostained with anti-G6Pase (red) and anti-albumin 
(green). (E). Appearance of G6Pase and albumin positive cells in 1 pM Dex or 1 pM 
Dex + 10 ng/ml OSM. Error bars are standard deviations.
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3.7 Transdifferentiation can occur without cell division
The. relationship between cell division and cell differentiation is one of the 
major long-standing problems in development and cell biology. In the classic view - 
the quantal cell cycle theory (Holtzer et al., 1975), there are two distinct cycles: (1) a 
proliferative cycle which acts to increase the number of the mother cells, and (2) a 
unique cell cycle which is responsible to the production of daughter cells different 
from the mother cells. In many cases of transdifferentiation, cell division and/or DNA 
replication is essential for transdifferentiation as the progress through cell cycles may 
cause the alteration of cell state and will cause a stable change in transcription 
mechanisms in the genome (Okada 1991). For example, in newt lens regeneration from 
the dorsal iris pigmented epithelium, activation of cell proliferation is a necessary 
condition for regeneration (Weber et al., 1987). But cell division and/or DNA 
replication are not essential to all instances of transdifferentiation. Weber also showed 
that in the transdifferentiation of striated muscle cells of jellyfish to smooth muscle 
cells can occurs directly without preceding cell division (Weber et al., 1987). 
Beresford provide a comprehensive list of cases of direct transdifferentiation 
(Beresford 1990). For example, a single glial progenitor cell can be converted to the 
oligodendrocyte by switch of medium without cell division.
In an independent set of experiments I examined whether cell division was an 
obligatory step in the transdifferentiation process of AR42J cells to hepatocytes (Fig.
3.7). The cells were labelled with BrdU from the first day of the Dex treatment. At 5 
days 51.5% of the cells expressing G6Pase had not incorporated BrdU so cannot have 
undergone an S-phase during transdifferentiation. The proportion is 68% if oncostatin 
M is added as well as the Dex. The remainder of the nascent hepatocytes were BrdU- 
labelled, as were many non-G6Pase expressing cells. Control (untreated) cultures
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showed a much higher labelling index due to the increased overall growth rate. This 
result shows that transdifferentiation to hepatocytes need not involve cell division.
The unlabelled cell count here represents a lower boundary on the proportion of 
cells transdifferentiating without cell division because some hepatocytes may have 
undergone an S-phase after the change of cell phenotype. These experiments prove 
that at least some of the hepatocytes arise by direct transdifferentiation of pancreatic 
exocrine cells without cell division. Exactly how many cannot be known and we 
cannot exclude the possibility that some hepatocytes also arise from stem cells or from 
other non-exocrine cells present in the cultures.
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Fig 3.12 Transdifferentiation to hepatocytes need not involve cell division. (A-C) 
Cells were incubated without or with 1 pM Dex and 10 ng/ml OSM for 5 days, 
continuous BrdU label from dayl, stained at day 5 with anti-G6Pase (red) and anti- 
BrdU (green). Many G6Pase positive cells have not incorporated BrdU. (D) 
Appearance of BrdU labeled cells in G6Pase expressing cells. Error bars are standard 
deviations.
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3.8 Determination of the stability of pancreatic hepatocytes
Basically, metaplasia (or transdifferentiation) is a unidirectional process from 
cell type A to B. Reversible change from B to A is rare. More precisely, the reversible 
change is outside the definition of transdifferentiation (Okada 1991). In order to 
determine whether or not the transdifferentiation is a unidirectional process, I 
investigated the stability of the pancreatic hepatocytes.
AR42J-B13 cells were treated for 2 weeks with 1 pM Dex, then split and 
cultured with 1 pM Dex and 10 ng/ml OSM for further 4 days to covert the cells into 
hepatocytes. Cells were then cultured in control medium without Dex, fixed after 4 
days and 10 days, then stained by hematoxylin, anti-transferrin or anti-amylase 
antibodies. As we can see from Fig 3.13, there are mainly two types of cells in the 
culture. The untransdifferentiated cells are smaller and the morphology is very similar 
to control AR42J-B13 cells. In contrast, transdifferentiated cells are larger. Removal of 
Dex increased the number of untransdifferentiated cells, but there are some 
transdifferentiated cells present. I further stained those cells with anti-transferrin or 
anti-amylase antibodies. Basically, we found some of cells expressing transferrin, and 
plenty of untransdifferentiated cells expressing amylase at a low level (Fig 3.14).
In addition, we tried to use green fluorescence protein driven by the TTR 
promoter to monitor the change in morphology after removal of Dex. AR42J-B13 cells 
were treated for 2 weeks with 1 pM Dex, then split and cultured with 1 pM Dex and 
10 ng/ml OSM for 4 days prior to transfection with CMV-nucGFP or TTR-nucGFP 
followed by exposure to 1 pM Dex and 10 ng/ml OSM for a further 72 hrs. Cells were 
then cultured in control medium without Dex, and the dish was photographed every 
other day with the confocal microscope. We found some of the cells lost their 
epithelia-like morphology and the proliferation of the untransdifferentiated cells was
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increased, but there were still some cells that can drive TTR promoter to express GFP 
protein. Although we cannot exclude the possibility that some of the cells 
dedifferentiated, these results at least suggest that the hepatic transdifferentiation is 
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Fig 3.13 AR42J-B13 cells were treated for 2 weeks with ljiM Dex, then split and 
cultured with 1 jiM Dex and 10 ng/ml OSM for further 4 days. Cells were then 
cultured in control medium without Dex, fixed after 4 days (C, G) and 10 days(D, 
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Fig. 3.14 AR42J-B13 cells were treated for 2 weeks with Dex, then split and 
cultured with 1 |iM Dex and 10 ng/ml OSM for further 4 days. Cells were then 
cultured in control medium without Dex, fixed after 4 days (B, E, H) and 10 days 







Fig.3.15 AR42J-B13 cells were treated for 2 weeks with lpM  Dex, then split and 
cultured with 1 pM Dex and 10 ng/ml OSM for 4 days prior to transfection with 
CMV-nucGFP or TTR-nucGFP followed by exposure to 1 pM Dex and 10 ng/ml 
OSM for a further 72 hrs. Cells were then cultured in control medium without 
Dex, and the dish was photographed each other day with the confocal microscope
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3.9 Discussion
The work in this chapter demonstrates the ability of the synthetic 
glucocorticoid dexamethasone to induce the formation of hepatocytes from pancreatic 
cells. As AR42J cells resemble a pluripotent pancreatic cell, we were interested to 
establish whether the transformation occurs at the level of a stem cell or of 
differentiated cells. Although our data cannot exclude a stem cell origin, we do show 
that at least some of the hepatocytes are formed directly from exocrine-like cells with 
no intervening cell division, and the hepatic transdifferentiation is basically a 
unidirectional process. This means that the process fits the definition of a 
transdifferentiation.
Dexamethasone is a synthetic glucocorticoid with a variety of effects on liver 
cells including the ability to induce the synthesis of albumin, transferrin, tyrosine 
aminotransferase, and glucose-6-phosphatase (Chou et al., 1988; Schmoll et al., 1996; 
Kamiya et al., 1999). It also enhances the differentiation of AR42J cells towards the 
exocrine phenotype (Logsdon et al., 1985). Our results suggest the possibility that 
endogenous glucocorticoids may be involved in the normal developmental decisions 
that operate to subdivide the foregut endoderm into stomach, pancreas, liver and 
intestine. Although Dex in combination with oncostatin M is known to accelerate the 
maturation process in fetal murine hepatocytes (Kamiya et al., 1999; Kinoshita et al., 
1999), these factors have not previously been considered to be embryonic inducing 
factors. On the other hand, fibroblast growth factors have been implicated in the 
primary induction of the liver (Jung et al., 1999), and have also been shown able to 
provoke hepatic metaplasia of the pancreas (Krakowski et al., 1999). It remains to be 
seen whether FGFs activate the same genetic pathway to induce hepatic differentiation.
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In a parallel experimental project, we started to use FGF treatment to trigger the 
transdifferentiation, but with limited success.
In sequences of elastase-GFP cells photographed on successive days it is 
possible to see a direct transformation of exocrine cells into flat cells. And we have 
shown that GFP can perdure from cells with an active elastase promoter into flattened 
cells expressing G6Pase. It indicates that at least some of the hepatocytes are formed 
directly from exocrine-like cells. This result may be compared to the observations 
from animal models which suggest hepatocytes might derive either from exocrine 
(Reddy et al., 1984), endocrine (Krakowski et al., 1999) or ductular cells (Makino et 
al., 1990). Because of the possibility of additional lineage pathways, we have 
examined whether other types of cells could be converted to hepatocytes. We have 
treated Rin-5F (rat pancreatic (3 cells), Capan-1 or PANC-1 (both human pancreatic 
duct cells) with Dexamethasone and/or Oncostatin M. These treatments were without 
effect although Dex treatment did cause the reduction of pancreatic phenotype on RIN- 
5F cells (data now shown, also see Chapter 6.4). Although we can not exclude the 
possibility that other type of pancreatic cells can transdifferentiate into hepatocytes, 
these negative results may suggest that glucocorticoid or the glucocorticoid signalling 
pathway is not sufficient to trigger the hepatic metaplasia from non-exocrine cells. 
Additional support for the exocrine-hepatocyte transdifferentiation is provided from 
the two cases of reverse conversion of hepatocyte to pancreas: (1) exocrine pancreatic 
tissue in the liver of rat induced by polychlorinated biphenyls (Rao et al., 1986a); (2) 
Exocrine pancreatic tissue in the liver of a 41-year-old patient with posthepatitic 
cirrhosis (Wolf et al., 1990). Both examples reflect the close relationship between 
pancreatic exocrine cells and hepatocytes. In the later chapters, I shall describe the use
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MOLECULAR BASIS OF TRANSDIFFERENTIATION 
OF PANCREAS TO LIVER
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4.1 Introduction
Liver and pancreas originate from the foregut endoderm (Zaret, 1998; Slack, 
1995). FGFs have been shown to be implicated in the specification of liver 
development (Jung et al., 1999), but the mechanism, which regulates the endodermal 
epithelium to develop into pancreas and liver, remains unclear. We presume there 
might be a gene(s) whose expression distinguishes these two tissues in normal 
development. Under certain conditions, a discrete change in this gene expression 
might cause the hepatic metaplasia of pancreas in postnatal life (see chapter 1). As a 
result, the system of hepatic metaplasia of pancreas provides a novel opportunity to 
elucidate the cellular and molecular mechanisms that control the development of two 
important endodermal organs- liver and pancreas.
Although hepatic metaplasia of the pancreas is well studied, there were only a 
few studies (Rao et al., 1989; Dabeva et al., 1995) to investigate the genes that are 
involved in the transdifferentiation. They both isolated the ductal epithelial progenitors 
from copper depletion-repletion (CuD) rats, and used the cells to investigate the 
mRNA level of liver enriched factors (LETFs). Their results show these cells express 
HNF-1, HNF-3a, HNF-3p, HNF-4, and members of the CCAAT/enhancer binding 
protein (C/EBP) family. However, as I described in Chapter 1.5, some of these 
transcription factors are also normally found to be present in the pancreas and other 
tissues (reviewed in Cereghini, 1996; Fig 4.1), so these results were not sufficient to 
understand the conversion of pancreatic cells to hepatocytes.
Liver-specific gene expression in adult hepatocytes relies on five families of 
evolutionary conserved transcription factors that are liver-enriched but not restricted to 
this tissue. They are hepatocyte nuclear factors 1, 3, 4, 6 (HNF-1, HNF-3, HNF-4, 
HNF-6) and CCAAT/enchancer-binding protein (C/EBP). These factors function in
64
unique combinations (Tronche and Yaniv, 1992; Simone and Cortese, 1992; 
Cereghini, 1996; Samadani and Costa, 1996; Darlington 1999), often synergistically, 
to stimulate cell-specific transcription. Each family is composed of several members 
displaying similar, if not identical, DNA recognition properties and sharing structural 
homology in their DNA binding domains. The homo- and heterodimerization between 
members of a particular transcription factor family adds an additional level of 
complexity in gene regulation.
We believe at least part of the process of metaplasia is governed by the 
combined action of the LETFs as they are actually involve in regulating many liver 
specific genes (Simone and Cortese, 1992). For example, Fig 4.2 shows the promoter 
region of albumin and transthyretin contained the binding site of HNF-1, HNF-3, 
HNF-4, and C/EBP. In order to determine how the combined actions of the LETFs to 
regulate the transdifferentiation process and/or liver differentiation, I have investigated 
the expression of LETFs in the transdifferentiation and also determine the importance 









Fig 4.1 Schematic representation of expression for liver enriched transcription factors 
in the different organs. The figure was modified from Tronche and Yaniv 1992; 
Cereghini 1996; Lekstrom-Himes and Xanthopoulos 1998.
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Fig 4.2 A diagram of the interactions between cis-acting elements and trans-acting 
factors in the promoters of albumin and transthyretin (TTR). The figure was modified 
from Simone and Cortese 1992.
67
4.2 Determination of genes involved in the conversion of pancreas to liver
In order to probe the molecular mechanism of the transdifferentiation process, 
we examined the expression of various transcription factors associated with hepatic 
differentiation. Our attention was initially drawn to molecules commonly regarded as 
liver transcription factors, namely HNF-1, HNF-3, HNF-4 and HNF-6. All of these 
factors are normally expressed in the liver, and most of them are also expressed in 
pancreas. For example, HNF-1, HNF-3p, HNF-4 and HNF-6 are normally expressed in 
pancreatic p cells. From the results obtained from RT-PCR, I found HNF-1, HNF-3p, 
HNF-3y, HNF-4 and HNF-6 are all expressed in AR42J-B13 cells. In comparison with 
the reduction of the pancreatic transcription factor-p48 (PTF-p48), which regulates the 
exocrine phenotype, the mRNA levels of these hepatocyte nuclear factors do not 
increase significantly on Dex treatment. Only the level of HNF-4 mRNA did increase 
slightly during the transdifferentiation (Fig 4.3).
Hepatocyte nuclear factor 4 (HNF-4), a member of the nuclear receptor 
superfamily (Sladek et al., 1990), is abundant in adult as well as the fetal liver and 
intestine, but is present at a lower level in islets of Langerhans and is scarcely 
detectable in exocrine pancreas (Miquerol et al., 1994). Although the level of HNF-4 
mRNA didn’t increase significantly, I tried to examine the protein level by 
immunstaining. I found the staining of HNF-4a increased after adding Dex to the 
culture (Fig.4.4 F-J). Noticeably, HNF-4a protein begins to translocate into the 
nucleus after 5 days of treatment with 1 pM Dex. The result suggests that HNF-4 
maybe involved in the process of the conversion of pancreas to liver.
CCAAT-enhancer binding proteins (C/EBP) are basic region/leucine zipper 
(bZIP) transcription factors expressed during the differentiation of adipose tissue and 
liver. As shown in Fig 4.1, we actually found that C/EBP is not normally expressed in
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the pancreas, so I decided to examine the level of C/EBP protein. As expected, we 
found that C/EBPp was absent from AR42J-B13 cells, but was induced after just 3d 
treatment with dexamethasone (Fig.4.4 A-E). Furthermore cells that had activated 
C/EBPp also show reduced amylase or increased G6Pase (Fig 4.5A, B). These 
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Fig 4.3 Time-course of mRNA level of hepatocyte nuclear factors 1, 3, 4, 6 and PTF- 
p48. Total RNA was extracted from cells incubated with 1 jllM Dex for 2, 4 days, 
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4.3 C/EBPp is a key component of the transdifferentiation process
To determine whether or not C/EBP is a key component of the 
transdifferentiation process? I decided to transfect AR42J-B13 cells with C/EBPp, and 
found that the effects were indeed very similar to those following Dex treatment. In 
cells expressing the C/EBPp, amylase fell and liver markers including transferrin, 
G6Pase and transthyretin became expressed (Fig 4.5E-H). These changes were 
unaffected by pretreatment with RU486 (Fig 4.6 D, H), which inhibits the Dex effect, 
showing that C/EBPp action is downstream of the glucocorticoid receptor activation. 
While the transfection of LAP, the constitutively active truncated form of C/EBPp, 
was also sufficient to cause the transdifferentiation. The result shows that the 
activation of C/EBPp is a critical step responsible for switching between pancreatic 
exocrine and hepatocyte phenotypes. Although transfection of C/EBPp caused hepatic 
differentiation, it does not cause the same degree of morphological flattening as the 
Dex treatment.
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Fig 4.5 C/EBP|3 induces transdifferentiation in AR42J-B13 cells. Cells were incubated 
with 1 |liM dexamethasone for 2 weeks and were then immunostained (A-D).
(A) anti-amylase (red) and anti-C/EBPp (green)
(B) anti-G6Pase (red) and anti-C/EBPp (green)
(C) anti-HNF-4a (green) and anti-C/EBPp (red).
(D) anti-amylase (red) and anti-HNF-4a (green)
Cells were transfected with pcDNA3-C/EBPp , and immunostained 4 days after(E-H).
(E) anti-C/EBPP (red) and anti-amylase (green).
(F) anti-C/EBPP (red) and TFN (green).
(G) anti-C/EBPp (red) and anti-G6Pase (green).







Fig 4.6 Overexpression of C/EBPp caused reduction in the expression of amylase and 
initiation of the expression of transferrin. AR42J-B13 cells were transfected with 
pcDNA-nucGFP (A) or pcDNA3 (E) or pcDNA-C/EBPp (B-D, F-H) without or with 
2.5 jiM RU486 (D, H). After 4 days of transfection, then stained with (A) Amy (red) + 
GFP (green) (B-D) Amy (red) + C/EBPp (green) or (E-H) TFN (green) + 
C/EBPP (red)
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4.4 Overexpression of LIP inhibits transdifferentiation
C/EBPp can be transcribed into one mRNA which can then be translated into 
three isoforms designated C/EBPp, liver inhibitory protein (LIP) and liver activator 
protein (LAP) (Descombe and Schibler, 1991). The LIP protein is a 21 kDa molecule 
which lacks the transactivation domain and acts as a dominant-negative form of 
C/EBPP by heterodimerising with the full length C/EBPp (Darlington 1999). 
Overexpression of LIP in 3T3-L1 fibroblasts has been shown to inhibit conversion to 
adipocytes, which is a C/EBPp-dependent process (Yeh et al., 1995).
To determine whether C/EBPP is an essential requirement for the 
transdifferentiation, I transfected LIP into AR42J-B13 cells under different culture 
conditions. CMV-LIP was transfected into AR42J-B13 cells and 24hrs later they 
were induced to undergo transdifferentiation by treatment of 1 jiM Dex and 10 ng/ml 
OSM. This treatment can induce more than 60% of AR42J-B13 cells to express 
G6Pase, TFN and TTR within 3 days. After 4 days of treatment the cells were 
stained for C/EBPP (or LIP) and G6Pase, TTR or TFN (Fig 4.7 A-L). The C/EBPP 
antibody used in this experiment was raised to the C-terminus, so it can recognise 
both C/EBPp and LIP. In all cells in which the LIP was present as determined from 
the more intense nuclear staining (Fig 4.7. C, G, K), the liver marker was absent, 
showing that overexpression of LIP is sufficient to prevent the transdifferentiation 
and suggests that C/EBPp is required for the conversion.
To investigate whether C/EBPp is necessary not only for induction, but also 
for maintenance of the hepatic phenotype I treated AR42J-B13 cells with Dex for 8- 
10 weeks, and then introduced LIP. In order to ensure that all cells were converted to 
hepatocytes, I pretreated the cells with 1 pM Dex and lOng/ml OSM for 5 days, then
transfected the cells with CMV-LIP and kept them in the medium containing 1 flM 
Dex and lOng/ml OSM for an additional 72hrs. Almost all of these cells express liver 
markers (G6Pase, TFN, or TTR), but the LIP positive cells lacked any of the liver 
markers compared to untransfected cells, showing that an existing hepatic phenotype 
can be inhibited by LIP (Fig 4.8 C, G, K). In cells transfected with control CMV- 
nuclear GFP, the level of liver marker expression was similar to the untransfected 
cells indicating that transfection itself was not responsible for preventing or inhibiting 
the markers expression (Fig 4.7 D, H, L; Fig 4.8 D, H, L). The results also indicate 













Fig 4.7 Inhibition of transdifferentiation by LIP. LIP can be detected by 
immunohistochemistry because the C/EBPp antibody is raised to the C-terminus. LIP 
transfected cells are much more intensely stained than those in which endogenous 
C/EBPp has been induced.
Cells transfected with CMV-LIP (A-C, E-G, I-K) and after 24hrs treated with 1 |iM 
Dex and 10 ng/ml OSM for 4 days. The cells were then immunostained for C/EBPP 
(red) and TFN (A, C), G6Pase (E, G) or TTR (I, K) (green) respectively.
Cells transfected with CMV-nucGFP (D, H, L) and after 24hrs treated with 1 |iM Dex 
and 10 ng/ml OSM for 4 days. The cells were then immunostained.for GFP (D, H, L) 
(green) and TFN (D), G6Pase (H) or TTR (L) (red). (B), (F) and (J) LIP transfected 
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Fig 4.8 C/EBPP is essential for maintenance of the transdifferentiation.
AR42J-B13 cells were treated for 8-10 weeks with 1 jxM Dex, then cultured with 1 (iM 
Dex and 10 ng/ml OSM for 5 days prior to transfection with CMV-LIP (A-C, E-G, I- 
K) or CMV-nucGFP (D, H, L), followed by exposure to Dex+OSM for a further 72 hrs 
and then immunostained for C/EBPP (red) and TFN (A, C), G6Pase (E, G) or TTR (I, 
K) (green) respectively, or GFP (D, H, L) (green) and TFN (D) , G6Pase (H) or TTR 
(L) (red). (B), (F) and (J) LIP transfected cells stain intensely (arrowed) whereas less 
intense cells show induced C/EBPP
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4.5 Regulation of epithelial morphogenesis in transdifferentiation
In epithelia, adhesive interactions participate in specific histogenetic events and 
also instate a morphological polarization that is linked to the vectorial functioning of 
the epithelium (Stamatoglou and Hughes, 1994). The polarised configuration of 
hepatocytes in the liver is crucial in maintaining liver function. When isolated 
hepatocytes are cultured in vitro, they lose the characteristic pattern of gene expression 
and their polarized configuration. Addition of hormones to the culture or growth of 
hepatocytes inside collagenous matrices or matrigel (Engelbreth-holm-swarm tumour- 
derived gel matrix) can counteract the polarized configuration and differentiation to 
varying degree (Jefferson et al., 1984; Isom et al., 1985; Duun et al., 1992; Ben-Ze’ev 
et al., 1988)
In previous chapters, we showed that following treatment with dexamethasone 
the pancreatic cells convert to cells expressing several liver-specific markers which are 
all expressed in differentiated hepatocytes. Associated with the transdifferentiation we 
also observed changes in cellular morphology. Following removal of Dex from the 
medium, we found some cells lost their epithelia-like morphology accompanied by 
loss of liver maker expression. The observations indicate that the mechanism 
regulating the transdifferentiation of pancreas to liver may also regulate hepatic 
morphogenesis and liver differentiation. As a result, this transdifferentiation model 
might provide us an opportunity to investigate the mechanisms involved.
We firstly analysed the expression of different cytoskeleton or cell adhesion 
markers which were known to be involved in formation of hepatic morphology and 
polarity including F-actin, Pan-cytokeratin, E-cadherin, and P-catenin. These results 
show that an increase of filopodia-like structures from day 2 is accompanied by the 
down-regulation of pancreatic amylase (Fig 4.9). Cells then become flattened,
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enlarged, express hepatic transferrin and form epithelial tight junctions which are 
associated with the expression of E-cadherin, and submembrane localisiation of P~ 
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Fig 4.9 Time course experiments showing that the hepatic transdifferentiation is 
associate with down-regulation of pancreatic amylase and expression of E-cadherin, 
and submembrane localisiation of P-catenin. Rearrangement of Pan-cytokeratins has 
also been observed during the transdifferentiation. AR42J-B13 cells were treated for 
2, 3, 5 days with 1 pM Dex and lOng/ml OSM, and then fixed and immunostained for 
amylase (Amy), transferrin (TFN), C/EBPp, HNF-4a, phalloidin-FITC (F-actin), Pan- 
Cytokeratin (PanCK), E-cadherin (E-cad) and p-catenin (b-cat). Arrows indicate the 
formation of filopodia-like structure.
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Previously, we have shown that transfection of LIP (liver inhibitory protein), 
the dominant negative form of C/EBPp is sufficient to inhibit transdifferentiation. 
Here, we also show LIP can also down-regulate the formation of filopodia-like 
structures, and the expression of cytokeratins and E-cadherin (Fig 4.10). In order to 
determine whether the morphogenesis is essential for the transdifferentiation, I decide 
to add cytochalasin D, an inhibitor of actin polymerisation, to the cultures to inhibit the 
morphogenesis. Here, we found addition of cytochalasin D at day 2 can prevent 
epithelial morphogenesis and onset of liver gene expression (Fig 4.11).
In order to determine whether the inhibitory effect was caused by the toxicity 
of the cytochalasin D, I remove cytoclasin D from day 3, and then cultured the cells 
with or without 1 pM Dex and 10 ng/ml OSM. The results showed that the cells can 
still transdifferentiate into hepatocytes (Fig 4.12) indicating cytochalasin D treatment, 
which prevents epithelial morphogenesis and hepatic transdifferentiation is not the 
effect of toxicity. It actually suggests epithelial morphogenesis may play an important 




Fig 4.10 Transfection of LIP can not only inhibit the expression of transferrin, but it 
can also down-regulate the formation of filopodia-like structures, and the expression of 
cytokeratins and E-cadherin. AR42J-B13 cells were transfected with CMV-DsRed (A- 
C) or LIP (D-H), and then treated with 1 pM Dex and 10 ng/ml OSM for 4 days and 
then immunostained for: DsRed (Red, A-C), C/EBPp (Red, D-F), transferrin (Green, 
A&D), phalloidin-FITC (Green, B&E), Pan-Cytokeratin (Green C&F), E-cadherin 
(Green, G) and p-catenin (Green, H)
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Fig 4.11 Addition of cytochalasin D can inhibit actin polymerisation, morphological 
changes and expression of transferrin. AR42J-B13 cells were treated with 1 |iM Dex 
and 10 ng/ml OSM for 2-3 days. Addition of 2.5 |iM cytochalasin D to some cultures 
at day 2 (C, I, O, F, L R), and then immunostained for phalloidin-FlTC (A-C), 
transferrin (D-F), Pan-Cytokeratin (G-I), C/EBPP (J-L), amylase (M-O), and HNF-4 
(P-R)
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Dex+OSM 3d Dex+OSM 3d Dex+OSM 5d Dex+OSM 5d Dex+OSM 3d2r Dex+OSM 3d2r
2.5 uM cD d2-d3 2.5 uM cD d2-d3 2.5 uM cD d2-d3
Fig 4.12 Removal of cytochalasin D from day 3 culture, cells can continue the 
transdifferentiation and morphogenesis programme. AR42J-B13 cells were treated 
with 1 pM Dex and 10 ng/ml OSM for 2 days, and then 2.5 pM cytochalasin D were 
added to some cultures at day 2 (B, H, N, D, J, P, F, L, R). Cytochalasin D was then 
removed from day 3, and cultured with (C-P) or without Dex+OSM (E-R). Cells were 




In the experiments described in this chapter, we have determined the molecular 
events associated with the transformation of AR42J-B13 cells to hepatocytes, are 
induction of C/EBPp followed by the nuclear translocation of HNF-4a and the 
activation of differentiated hepatic products. Transfection of C/EBPp into the cells can 
itself provoke the transdifferentiation while LIP (liver inhibitory protein), the 
dominant-negative form of C/EBPp can inhibit the process, suggesting that C/EBPp is 
a key component distinguishing between the liver and pancreatic programs of 
differentiation.
The results mimic the hepatic metaplasia of pancreas observed in animal 
experiments. In the copper deprivation regime the exocrine pancreas mainly 
degenerates and becomes replaced by fibrous tissue. When the animals are re-fed on a 
normal diet there is a rapid accumulation of fat in this interstitial tissue. The exocrine 
acini then regenerate over several weeks from small foci, and are accompanied by the 
growth of foci of hepatocytes. So in the course of this treatment, individual surviving 
exocrine cells would be exposed to conditions very different to those experienced in 
the normal intact pancreas. Since C/EBPP is known to be involved in adipogensis 
(Tanaka et al., 1997; Darlington et al., 1998), the accumulation of fat in the interstitial 
tissue could be caused by the generation of C/EBPp. C/EBPa, p and 5 mRNAs have 
been shown to increase in copper-deprived pancreas, at about 4-5 weeks, just before 
the appearance of visible hepatocytes. It is therefore likely that C/EBPp is involved in 
the process of metaplasia in vivo, but it is not determined whether the C/EBPs are 
directly involved in the process.
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Evidence from mouse knockouts have so far not shown a major function in 
normal liver development for C/EBPs, but C/EBPp has been shown to act as a key 
gene for liver regeneration (Diehl 1998). Actually, the knockouts of C/EBP a  and 
C/EBPp do have slight liver defects (Wang et al., 1995; Screpanti et al., 1995; Liu et 
al., 1998). We suspect that simultaneous knockouts of all C/EBP type genes may 
cause a major liver defect and it is significant that the deletion of the C/EBP 
homologue in Drosophila is embryonic lethal (R0rth and Montell, 1992). Additionally, 
in vivo footprinting shows that in embryonic hepatocytes, C/EBPp is actually bound to 
the albumin gene enhancer (Bossard et al., 1997). This result indicates a role of 
C/EBPp in fetal liver development.
The hepatocyte nuclear factor 4 (HNF-4) is a member of the nuclear receptor 
superfamily (Sladek et al., 1990; Mangelsdorf and Evans, 1995). These factors 
normally exist in the cytoplasm, and the ligand-induced translocation to the nucleus is 
an important step in regulating their target gene transcription. HNF-4 is abundant in 
adult as well as the fetal liver and intestine, but is present at a lower level in islets of 
Langerhans and is scarcely detectable in the exocrine pancreas (Miquerol et al., 1994). 
HNF-4 is known to play a critical role in regulating the function of normal pancreatic 
P-cell, because a mutation in this factor causes maturity onset diabetes of the young 
type 1 (MODY1) (Yamagataet al., 1996b).
The importance of HNF-4 in liver differentiation comes from oval cell 
regeneration. If rats are treated with aminoacetyl-fluorene to inhibit hepatocyte growth, 
then subjected to partial hepatectomy, liver regeneration proceeds from oval cells 
associated with the bile ducts (Alison et al., 1998). During this process, the expression 
of HNF-4 is first observed when the oval cells differentiate morphologically and 
functionally into hepatocytes (Nagy et al., 1994). These results all imply that the
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activity of HNF-4 plays a critical role in regulating liver differentiation, both in 
development and in regeneration.
Weiss and coworkers found HNF-4 expression overcomes repression of the 
hepatic phenotype in dedifferentiated hepatoma cells, and glucocorticoid enhances this 
effect (Spath and Weiss, 1997; 1998). They also found a similar phenomenon as we 
describe here in that the differentiation is associated with growth arrest. Furthermore, 
Weiss and colleagues also suggest that HNF-4 seems to integrate the genetic programs 
of liver-specific gene expression and epithelial morphogenesis (Spath and Weiss 
1998). They found HNF-4 is sufficient to provoke reexpression of a set of hepatocyte 
marker genes and also to the reestablishment of differentiated epithelial cell 
morphology and simple epithelial polarity in dedifferentiated rat hepatoma H5 cells. 
Expression of HNF-4 results in reexpression of cytokeratin proteins and partial 
reestablishment of E-cadherin production. Only the HNF-4 transfectants are 
competent to respond to the synthetic glucocorticoid dexamethasone, which induces 
the second step of morphogenesis, including formation of the junctional complex and 
expression of a polarized cell phenotype.
Recently Fuchs and coworkers found Calcium stimulates formation of 
filopodia in keratinocytes, which penetrate and embed into neighboring cells. E- 
cadherin complexes cluster at filopodia tips, generating a two-rowed zipper of 
embedded puncta (Vasioukhin et al., 2000). In this chapter I demonstrate that 
enhancement of actin polymerisation and formation of filopodia-like structures during 
the early phase, which may promote cells to make initial contact with neighbours. 
Cells then become flattened, start to express hepatic transferrin and form epithelial 
tight junctions which are associated with expression of E-cadherin, and submembrane 
localisiation of (3-catenin. Rearrangement of cytokeratin proteins has been shown to
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occur during the transdifferentiation. Cytochalasin D can prevent epithelial 
morphogenesis and liver gene expression suggesting a possible role for microfilaments 
in the transdifferentiation process. These results suggest epithelial morphogenesis may 
play an important role in the hepatic transdifferentiation of pancreas, but it remains to 
be determined whether HNF-4 is essential.
In the developing mouse, HNF-4 is normally expressed in the early visceral 
endoderm, an extraembryonic tissue which shares many biochemical features with the 
liver. Disruption of the HNF-4 genes in visceral endoderm blocks the expression of a- 
fetoprotein, apolipoprotein, transthyretin and transferrin (Duncan et al., 1997). The 
knockout mouse dies early because of failure of the visceral endoderm. Recent studies 
performed by Duncan and his colleagues showed that HNF-4 -/- fetal liver failed to 
express a large array of genes, which are essential for hepatic function (Li et al., 2000). 
The results suggest an essential role of HNF-4 in liver differentiation.
We therefore propose that the transformation from pancreas to liver arises from 
a molecular pathway in which Dex activates the glucocorticoid receptor; this activates 
transcription of C/EBPp, and translocation of HNF-4a to the nucleus and activation of 
target genes. The target genes comprise cti -antitrypsin, transferrin, transthyretin and 




HEPATOCYTES IN PANCREATIC BUD CULTURE
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5.1 Introduction
The mature pancreas has morphologically and functionally distinct endocrine 
and exocrine components. The exocrine portion, including acinar and ductal cells, 
comprises 95%-99% of the pancreas and produces digestive enzymes that promote 
nutrient digestion and absorption in the gut. Mature endocrine cells are located in the 
islets of Langerhans and aggregated scattered throughout the exocrine pancreas. Islets 
contain four principal endocrine cell types, defined by the hormones they secrete. 
These include insulin-producing fi-cells, glucagon-producing a-cells, somatostatin- 
producing 6-cells, and pancreatic polypeptide-producing PP cells. All pancreatic cell 
types (endocrine, exocrine, and ductal) are derived from the same endodermal dorsal 
and ventral primordium, which grow together to form the definitive pancreas. (Slack 
1995; Edlund 1999; Kim and Hebrok, 2001)
Early pancreatic development has been particularly well studied in mice and 
chickens, and important similarities and differences in pancreatic morphogenesis in 
these species have been previously described (Kim et al. 1997b). Here, I will briefly 
describe the development of the pancreas in mice. During embryogenesis, the 
pancreas develops from distinct dorsal and ventral anlagen. Before specification 
toward a dorsal pancreatic fate, the midline endoderm in the posterior foregut is a 
single layer of epithelial cells that contacts the notochord, an axial mesoderm-derived 
structure (Kim and Hebrok, 2001). Laterally, endoderm fated to form ventral pancreas 
is adjacent to both splanchnic mesoderm and aortic endothelial cells but is not in direct 
contact with the notochord. The notochord and dorsal pancreatic endoderms remain in 
contact until about the 13-somite stage in mice (8.5d postcoitum (dpc)), when midline 
fusion of the paired dorsal aortas occurs. The first indication of morphogenesis occurs 
at 22-25 somites in mice (9.5 dpc), when the dorsal mesenchyme condenses and
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underlying endoderm evaginates, forming a recognizable dorsal pancreatic bud; the 
ventral bud appears later at 30 somites (10.5 dpc). Stimulated by mesenchymal signals, 
pancreatic epithelial cells proliferate and branch (Slack 1995; Kim and Hebrok, 2001).
In the developing pancreatic buds, the endocrine cells start to differentiate 
before the exocrine cells, and co-expression of different hormones by the same cell is 
often observed at early stages. Although pancreatic endocrine cells produce many 
gene products also characteristic of neurons, evidence from in vitro cultures and from 
chick grafts shows that they are of endoderm and not of neural crest origin. 
Observational and experimental recombination studies suggest strongly that both 
endocrine and exocrine cells arise from the same endodermal rudiment (Slack 1995; 
Percival and Slack, 1999).
Assuming that the principles of development as established by work on early 
embryos holds also for organ development, there must be a region within the 
endoderm committed to form the pancreas at some stage before the appearance of the 
first terminal differentiation products. This region presumably consists of a set of cells 
committed by the expression of a particular combination of transcription factors. 
Obviously, it would be good to know the identity of the genes involved in the 
specification of the pancreas. Golosow and Grobstein were pioneers in the field of 
pancreas developmental research, as were Wessells and Cohen, who already in the 
1960s performed classic embryological experiments describing the morphogenesis of 
the pancreas and the epithelio-mesenchymal interactions that are instrumental for 
proper pancreas development. Recent findings suggest that follistatin and fibroblast 
growth factors represent some of these key mesenchymal factors that actively promote 
at least pancreatic exocrine development (Review in Edlund 2001). The early steps 
that control the commitment of a region of localized gut epithelium to a pancreatic fate
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and the mechanism underlying the specification of the different pancreatic cell types 
are, however, not well understood. One approach to determining the mechanism is to 
investigate the occurrence of heterotopic pancreas in the embryo, and also the hepatic 
metaplasias that can be displayed by a regenerating pancreas in the adult. Both 
suggest that only a few gene products distinguish the pancreatic cell state from that of 
the surrounding tissues of duodenum, gall bladder and liver (Slack 1995).
In previous chapters, I have shown that dexamethasone can induce pancreatic 
AR42J-B13 cells to transdifferentiate into hepatocytes. Like all tissue culture cells, the 
AR42J-B13 cells are undoubtedly somewhat altered since their ancestors were isolated 
20 years ago. In order to establish that the results obtained were not just a tissue 
culture artifact but were relevant to the situation in vivo, in this chapter we studied the 
effects of dexamethasone on pancreatic buds isolated from mouse embryos.
5.2 Development of pancreatic buds in vitro
In mice, soon after specification of the pancreatic anlage in posterior foregut 
endoderm at 8.5 dpc, somatostatin mRNA becomes detectable, marking the beginning 
of endocrine cell differentiation (Herrera et al. 1991; Gittes and Rutter 1992). 
Immunolocalisation demonstrates the appearance of scattered cells expressing insulin 
or glucagon from 9.5 dpc. Development of exocrine cells into acini and ducts is 
recognizable by 14.5 dpc; at this stage, endocrine cells are found embedded as 
individual cells in ducts or in small cell clusters distinct from ducts. The stereotyped 
architecture of islets with central insulin-expressing p-cells surrounded by a-cells is 
detected late in gestation from 18 dpc (Slack 1995; Edlund 1999; Kim and Hebrok, 
2001).
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Golosow and Grobstein (1962) found that an 11.5d mouse pancreatic bud 
would develop very well in vitro, but that the isolated epithelium would not grow or 
differentiate in the absence of mesenchyme (Reviewed in Kim and Hebrok, 2001). 
Previously our lab have devised a new culture system for in vitro culture of pancreatic 
buds from mouse embryos which enables the organ to grow as a flat branched structure 
suitable for wholemount immunostaining (Percival and Slack 1999). This system has 
been used to analyze pancreatic development (Percival and Slack 1999; Horb and 
Slack 2000).
The dorsal buds were isolated from E l 1.5 mouse embryos. The buds adhere to 
the fibronectin substrate within a few hours and gradually flatten out over the first 1-2 
days. Mesenchymal cells spread rapidly out of the explant to form a monolayer of 
cells surrounding the clump in the centre. On the second or third day, branches begin 
to appear in the epithelium. We can find the appearance of scattered cells expressing 
insulin or glucagon, which became quite numerous from 13.5 days onward (Fig 5.1 A). 
Over the next 3 days, the epithelium becomes an extended branched structure radiating 
from the original centre, and development of exocrine cells can be recognized (Fig 
5. IB). Insulin cells are very few and faintly stained after 1 and 2 days of culture, but 
become more numerous and strongly stained thereafter. Clumps of endocrine cells 
resembling nascent islets can be seen scattered from day 6 (Fig 5.1C, D).
Our time course experiments showed that the cell differentiation in the cultures 
resembles quite closely what occurs in vivo although it occurred slightly later in time, 
the delay being about 1 day over a 4-day culture period. By contrast, as for all organ 
cultures of this type, the overall growth in size of the cultures is very much less than 




Fig 5.1 Development of pancreatic buds ex vivo Buds were cultured for 3, 5 7 and 
10 days, fixed and stained for amylase (green), insulin (red) and glucagon (blue)
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5.3 Formation of hepatocytes in pancreatic bud culture
In previous chapters, I have shown that dexamethasone can induce pancreatic 
AR42J-B13 cells to transdifferentiate into hepatocytes. Here, I would like to determine 
whether treatment with Dex can caused the hepatic transdifferentiation in pancreatic 
bud cultures. Dorsal pancreatic buds were isolated from 11.5d embryos and 
maintained in culture. After two days, Dex was added to the cultures. Firstly, we 
observe branching morphogenesis was reduced. After 5 days of Dex treatment, 
hepatocytes begin to appear within the buds as judged from expression of albumin, 
transferrin and ai-antitrypsin (Fig.5.2). The result shows that the phenomenon of Dex- 
induced transdifferentiation is not restricted to the AR42J-B13 cells but applies equally 
to the normal developing pancreas.
The results obtained from AR42J-B13 cells suggest C/EBP(3 is a key gene in 
the hepatic transdifferentiation, so I wanted to determine whether or not C/EBPp is 
involved in the conversion in pancreatic bud culture. Firstly, I found that C/EBPp was 
not normally expressed in the pancreatic buds, but became activated in many cells 
following Dex treatment, with concurrent reduction of amylase expression and 
activation of albumin expression in these cells (Fig.5.2E, Fig 5.3). The result again 
support the notion that C/EBPp plays a major role in the transdifferentiation of 
pancreas to hepatocyte.
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Fig 5.2 Hepatic transformation in pancreatic buds from mouse embryos. Buds were 
cultured for 5 days without (A-E) or with 1 pM Dex (F-J), then immunostained for (A, 
F) albumin (green) / amylase (red). (B, G) glucose-6-phosphatase (green) / amylase 
(red). (C, H) transferrin (green) / insulin (red). (D, I) ai-antitrypsin (green) / insulin 







Fig 5.3 C/EBPp expression during the hepatic differentiation in pancreatic buds from 
mouse embryos. Buds were cultured for 5 days without (A-B) or with (C-D) 1 pM 
Dex.
(A) Control, anti-C/EBPp (green) and anti-amylase (red). C/EBPp is not expressed.
(C) Dex treated, anti-C/EBPp (green) and anti-amylase (red). C/EBPp is expressed.
(B) Control, anti- C/EBPp (red) and anti-albumin (green). Neither is expressed.
(D) Dex treated, anti-C/EBPp (red) and anti-albumin (green). All cells expressing 
albumin also show C/EBPp
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Recently, Zaret and colleagues used tissue explant studies from 8.5 to 11.5 days 
gestation embryos to show that when the gut mesoderm is removed from the 
prospective intestinal endoderm, the endoderm activates the expression of liver- 
specific genes such as serum albumin, demonstrating the endoderm's pluripotence. But 
they also suggest at 13.5 d, the mesoderm gains a second inhibitory activity, resulting 
in the irreversible loss of plasticity (Bossard and Zaret 2000). In order to determine 
whether dexamethasone-induced hepatic transdifferentiation can occur after this stage, 
I set up bud culture from 13.5d embryos, and incubated for the further two days, then 
added Dex to the culture. After 5 days of Dex or Dex + OSM treatment, we still can 
find cells expressing transferrin (Fig 5.4), and there was no difference in expression of 
transferrin between Dex and Dex + OSM treatment. This result suggests that Dex 
treatment is sufficient to overcome the commitment of pancreatic development and 
redirect the cells to transdifferentiate into hepatocytes
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Control Dex Dex + OSM
Fig 5.4 Hepatic transformation in pancreatic buds from 13.5d mouse embryos. Buds 
were isolated from 11.5d (A-C) or 13.5d (D-F) mouse embryos. After two days, bud 
cultures were incubated without (A, D) or with 1 |LiM Dex (B, E) or 1 pM Dex + 10 
ng/ml OSM (C, F) for 5 days. And then immunostained for anti-transferrin (green) 
and anti-insulin (red)
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5.4 Origin of pancreatic hepatocytes
The accumulated evidence is consistent with the possibility that a unique cell 
gives rise to all pancreatic cell lineages although the existence of such a pancreatic 
“stem” cell remains debatable. In the AR42J-B13 cells, we set up a perdurance 
experiment to prove that some of hepatocytes arise from differentiated exocrine cells. 
Unfortunately, a similar lineage experiment is difficult to set up in organ culture 
because we are unable to transfect genes into the epithelium (data not shown). 
Interestingly, when Dex-treated cultures were stained for both albumin and amylase, it 
was found that albumin expression was often present in cells that are also positive for 
amylase. This was even more noticeable when the Dex was accompanied by 
oncostatin M (Fig.5.5). The finding is different from the result we have seen in 
AR42J-B13 cells- where the amylase is lost from all cells that have reached the stage 
of albumin expression, so in this respect the two systems differ. But the observation 
does support the conclusion from our GFP perdurance experiment on the AR42J-B13 
cells that at least some of the hepatocytes arise by direct transdifferentiation from 
pancreatic exocrine cells. Again, it is not possible to say that hepatocytes do not also 
arise from stem cells or other types of progenitor cells.
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Fig 5.5 Dex treatment caused co-expression of amylase (red) and albumin (green) in 
some cells. Buds were cultured for 5 days without (A) or with 1 pM Dex (B-C) or 1 
|iM Dex + lOng/ml OSM (D). Yellow staining indicates co-expression of amylase 
(red) and albumin (green) in the same cells.
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5.5 Retinoic acid affects the development and hepatic metaplasia of pancreatic buds
Retinoic acid has been shown to inhibit the growth of both pancreatic ductal 
DSL-6 A/Cl cells in vitro and azaserine-induced foci in the rat pancreas (Brembeck et 
al., 1998; Roebuck et al., 1984). Recent studies in our lab demonstrate that cell 
division is necessary for branching morphogenesis and exocrine differentiation. 
However, endocrine cells can arise from undifferentiated progenitors without cell 
division (Horb and Slack 2000). Interestingly, when I added all trans-retinoic acid into 
the culture, we found the concentration of lOOnM can inhibit branching morphogenesis 
and exocrine differentiation (Fig 5.6), but not endocrine differentiation (Fig 5.7). A 
reduction in the number of CK20 expressing duct cells was also observed.
When we added both Dex and Retinoic acid into culture, I found that the 
proportion of cells undergoing transdifferentiation to hepatocytes was lower than Dex 
treated buds, and the inhibition of exocrine differentiation was also reduced (Fig 5.8). 
Although the mechanism regulating the differentiation of pancreatic exocrine cells 
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Fig 5.6 Effect of different concentrations of all trans-retinoic acid on pancreatic buds. 
Buds were cultured for 5 days with DMSO or with 100 nM -  10 pM retinoic acids, 
fixed and stained for amylase (green) and insulin (red).
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Fig 5.7 Effect of retinoic acid on pancreatic bud development. Buds were cultured for 
3 days (A, E) or 5 days (B-D, F-H) with DMSO (A-D) or with 1 pM retinoic acid (E- 
H), fixed and stained for (A, E) amylase (B, F) amylase (green)/ insulin (red) (C, G) 
glucagon (green) / insulin (red) (D, H) CO O (green) / insulin (red).
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Fig 5.8 Effect of retinoic acid on hepatic transdifferentiation in pancreatic buds. Buds 
were cultured for 5 days with DMSO (A, E, I, M), 1 |iM retinoic acid (B, F, J, N), 1 
pM retinoic acid + 1 pM Dex (C, G, K, O), or 1 pM Dex + DMSO (D, H, L, P) fixed 




In this chapter, the results demonstrate that treatment of mouse embryo 
pancreatic buds with Dex also yields hepatocytes, showing that this effect is not simply 
a tissue culture artifact but mimics a normal developmental switch. The co-localisation 
of amylase and albumin in some cells does support the conclusion from our GFP 
perdurance experiment on the AR42J-B13 cells that at least some of the hepatocytes 
arise by direct transdifferentiation from pancreatic exocrine cells.
We still cannot exclude the possibility of the stem cells exist in foetal pancreas. 
Lollis and coworkers have examined foetal pancreases which were obtained from 
spontaneous abortions (Tsanadis et al., 1995), and found the presence of a 
characteristic cell-type whose morphology was distinct from islets cells and exocrine 
pancreas cells was observed in human foetal pancreatic islets. These cells were 
morphologically similar to hepatocyte-like cells and were comparable to those 
observed in the experimental models. The result does suggest hepatic precursors exist 
in the human foetal pancreas. Recent studies performed by Zaret’s lab also support the 
idea. They found there are bipotential precursor cells for pancreas and liver in 
embryonic development (Deutsch et al., 2001). They suggest that the default fate of 
the ventral foregut endoderm is to activate the pancreas gene program, and FGF 
signalling from the cardiac mesoderm diverts this endoderm to express genes for liver 
instead of those for pancreas. If so, our results may also indicate that the 




GLUCOCORTICOIDS, PANCREATIC DEVELOPMENT 
AND ADULT DIABETES
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6.1 Introduction to diabetes
Diabetes mellitus is a major public health problem, affecting -5% of the 
western population, and its treatment consumes more than 10% of the total National 
Health Service budget in Britain. The chronic complications of diabetes cause 
enormous human suffering in the form of blindness, kidney failure, limb amputations, 
and increased risk of coronary artery disease (CAD). There are two common forms of 
diabetes: Type I diabetes (Insulin dependent diabetes mellitus, IDDM) and Type II 
diabetes (Non-insulin dependent diabetes mellitus, NIDDM).
Type I diabetes is caused by autoimmune destruction of pancreatic p-cells, 
leading to a near total deficiency in insulin secretion in response to biological needs. 
Therefore, the treatment of type I diabetes is complicated all too often by episodes of 
hypoglycemia or hyperglycemia. Unfortunately, hypoglycemia can cause coma, and 
hyperglycemia increases the risk of developing diabetic complications such as 
blindness and kidney failure (Tisch and McDevitt 1996).
Type II is the commonest form of diabetes, accounting for > 90% of diabetic 
patients. It is caused by two physiological defects: resistance to the action of insulin 
combined with a deficiency in insulin secretion (Defronzo, 1997). Although the 
molecular defects causing diabetes are not yet clear, basically it has been found that (1) 
genetic factors determine the risk of developing type II diabetes, (2) the presence of 
insulin resistance predicts future development of type II diabetes, and (3) patients 
become diabetic if they develop insulin deficiency due to failure of pancreatic P-cell 
(Taylor, 1999). There are a few genes have been identified that cause the common 
form of type II diabetes or has been found to involve in the mechanism that cause 
insulin deficiency and insulin resistance.
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The insulin gene was the first target to be identified as a type II diabetes gene 
(Steiner et al., 1990). Mutations in the insulin gene either inhibit conversion of pro­
insulin to insulin or reduce the affinity of insulin for its receptor. Recently, several 
genes have been identified as causes of maturity onset-type diabetes of youth 
(MODY), an early-onset form of type 2 diabetes transmitted with autosomal dominant 
inheritance. One example is the glucokinase gene (Bell et al., 1996). Glucokinase 
phosphorylates glucose to glucose-6-phosphate and plays an essential role in the 
glucose-sensing mechanism of P cells. Mutations in this gene lead to a partial 
deficiency of insulin secretion. In other forms of MODY, mutations have been 
identified in various transcription factors: hepatocyte nuclear factor HNF-la, HNF-4a, 
Pancreatic duodenal homeobox-1 (PDX-l/IPF-l/IDX-1), and HNF-ip in MODY1, -3, 
-4, and -5, respectively (Yamagata et al., 1996a, 1996b; Stoffers et al., 1997; 
Horikawaet al., 1997). These transcription factors are expressed in pancreatic p cells, 
and are known to regulate insulin expression. The mutations are believed to cause 
insulin deficiency by impairing p cell function. However, because HNFs are also 
expressed in hepatocytes these mutations may cause abnormalities in hepatic glucose 
metabolism as well.
The insulin receptor, a ligand-stimulated tyrosine kinase, mediates the first 
steps in insulin action (White and Yenush, 1998). The activated receptor 
phosphorylates multiple proteins—e.g., insulin receptor substrates (IRS)-l, -2, -3, and 
-4. Phosphorylation of tyrosine residues in these substrates leads to activation of 
multiple downstream signalling pathways. For example, activation of 
phosphatidylinositol (PI) 3-kinase triggers a cascade of serine/threonine protein 
kinases including protein kinase B and atypical isoforms of protein kinase C, which 
mediate the metabolic actions of insulin (i.e. stimulation of glucose transport enzymes
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in muscle and adipose tissue, and regulation of the expression and activity of key 
metabolic enzymes). Mutations in the insulin receptor gene (.IR) cause several 
uncommon syndromes associated with severe insulin resistance, including 
leprechaunism and type A insulin resistance (Taylor, 1992), but have also been 
reported in a small percentage of patients with type 2 diabetes. Amino acid sequence 
variants have been identified in IRS1, but their role in causing diabetes is controversial 
(Almind et al., 1996; Imai et al., 1997). Diabetes has not been demonstrated to be 
associated with mutations in genes encoding other proteins in the insulin action 
pathway. Indeed, when the p85a subunit of PI 3-kinase was knocked out, the mice 
developed increased insulin sensitivity and hypoglycemia rather than diabetes 
(Terauchi et al., 1999).
Type II diabetes is a complex heterogeneous disease with multiple genes 
contributing to the cause of this polygenic disorder. Defects in the insulin action 
pathway may be the cause of insulin deficiency in some patients, but there may also be 
patients in whom there are primary genetic defects that directly impair the machinery 
for insulin secretion. Type II diabetes is widely believed to be genetically determined, 
but epidemiological observation has consistently revealed statistical association 
between poor fetal growth and loss of glucose tolerance in adult life (Phillips 1998; 
Phillips et al., 1998; Hales 1993; Hill and Duvillie 2000). A possible explanation of 
these observations is that environmental constraints on fetal growth lead to permanent 
changes in organogenesis. Although the molecular mechanisms underlying this link 
are unknown, Seckl and colleagues have provided evidence in animal experiments to 
show fetal glucocorticoid exposure may play a role (Lindsay et al; 1996b; Nyirenda et 
al., 1998; Nyirenda and Seckl 1998). This finding is of interest. In the previous 
chapters, I presented evidence to show that glucocorticoid can induce hepatic
metaplasia in pancreatic bud cultures. In this chapter, firstly I will discuss the 
correlation between glucocorticoid, fetal programming and diabetes in adult life, and 
secondly present evidence to show that glucocorticoids can also cause defects in 
pancreas development, which may lead to the development of type II diabetes in adult.
6.2 Glucocorticoid, fetal programming and adult diabetes
Low birth weight is an important risk factor for type II diabetes in later life. 
Maturity-onset diabetes of the young has been linked to genetic sequence 
abnormalities in transcription factors known to be involved in endocrine pancreatic 
development. These observations suggest that both the maternal environment and the 
fetal genome can influence the number and/or function of pancreatic beta cells in early 
life, and that this has life-long implications for postnatal development of diabetes.
Studies in Europe, North America, and the developing world have shown that 
low birth weight and other indices of abnormal fetal growth in babies are linked with a 
higher prevalence of glucose intolerance and type II diabetes in adult life (Evidence 
reviewed in Phillips, 1998). Reduced fetal growth is also associated with a higher 
prevalence of the metabolic syndrome (in particular, hypertension and vascular 
disease) and with insulin resistance in adult life. The concept of fetal "programming" 
has been advanced to explain this phenomenon (Seckl et al., 2000). Fetal adaptations 
to an adverse intrauterine environment that reduces fetal growth programme results in 
lifelong physiological changes. These changes in turn predispose to diabetes and the 
metabolic syndrome. The mechanisms are unknown, but evidence from animal studies 
and preliminary human evidence suggests that adverse events in early life may 
influence the neuroendocrine development of the fetus.
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One possible link between low birth weight and type II diabetes in adult life is 
fetal glucocorticoid exposure. Glucocorticoids (corticosterone in rats and mice, cortisol 
in most other mammals) are produced by the adrenal cortex. In adult mammals, 
glucocorticoid hormones are involved in control of several physiological processes that 
maintain homeostasis including coordination of responses to stress (Geley et al., 1996). 
During development, glucocorticoids have important regulatory functions to prepare 
the organism for metabolic adaptations necessary for extrauterine life. Normally, the 
fetus has much lower levels of physiological glucocorticoid than its mother (Campbell 
and Murphy, 1977). Supra-physiological doses of glucocorticoids retard fetal growth, 
and human intrauterine growth retardation is associated with elevated cortisol levels 
(Reinisch et al., 1978).
Fetal glucocorticoid load is, in part, regulated by placental and fetal 1 lp- 
hydroxysteroid dehydrogenase type 2 (llp-HSD2) which catalyses a rapid breakdown 
of maternal and fetal glucocorticoids into inert 11-keto forms, cortisone and 11- 
dehydrocorticosterone (Benediktsson et al., 1997). Normally, llp-HSD2 in the 
placenta and some fetal tissues is thought to protect the fetus from excess maternal 
glucocorticoids.
Studies performed by Seckl and colleagues have shown that in rats, birth 
weight is reduced following either prenatal exposure to the synthetic glucocorticoid 
dexamethasone, which readily crosses the placenta, or to carbenoxolone, which 
inhibits 11P-HSD2, the physiological feto-placental "barrier" to endogenous 
glucocorticoids. (Lindsay et al., 1996) Although the offspring regain the weight deficit 
by weaning, as adults they exhibit permanent hypertension, hyperglycemia, and 
increased hypothalamic-pituitary-adrenal axis activity. Moreover, physiological
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variations in placental 1 lp-HSD2 activity near term correlate directly with fetal 
weight. In humans, 11P-HSD2 gene mutations produce a low birth weight, and some 
studies show reduced placental llp-HSD2 activity in association with intrauterine 
growth retardation. Moreover, low birth weight babies have higher plasma cortisol 
levels throughout adult life, indicating that hypothalamic- pituitary-adrenal axis 
programming also occurs in humans (Seckl 2000).
Administration of dexamethasone (a poor substrate for llp-HSD2) to pregnant 
rats in the last week of pregnancy reduces birth weight by 10%, and produces adult 
fasting hyperglycemia, reactive hyperglycemia, and hyperinsulinemia on oral glucose 
loading. In the adult offspring of rats exposed to dexamethasone in late pregnancy, 
hepatic expression of phosphoenolpyruvate carboxykinase (PEPCK) mRNA (and 
activity) is increased by 60% (Nyirenda et al., 1998). These observations indicate that 
programmed PEPCK overexpression in liver promotes gluconeogenesis which may 
cause glucose intolerance in adulthood. This animal model of glucocorticoid 
programming may provide a chance to explain the association between fetal growth 
and subsequent disorders in adult life including type II diabetes.
As I mentioned earlier in this chapter, type II diabetes may be caused by either 
or both of two physiological defects: resistance to the action of insulin and defects in 
insulin secretion. The aim of the following sections of this chapter was to determine 
whether glucocorticoid exposure during embryogenesis might cause defects in 
pancreatic development and whether hepatic metaplasia of the pancreas also occurs.
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6.3 Glucocorticoid and abnormal development of the pancreas
In the previous chapters, I presented evidence to show that pancreatic cells can 
be converted into hepatocytes by glucocorticoid treatment. This occurs both in a 
pancreatic cell line, AR42J-B13, and in organ cultures of pancreatic buds from mouse 
embryos. In order to investigate whether treatment with glucocorticoid in mid-late 
gestation can affect the pancreas development itself, further experiments were carried 
out. Different concentrations of Dex (from 1 nM to 1 pM) were added to the 2d 
pancreatic bud cultures and incubated for 5 days. As expected, there were some 
hepatocyes formed in the 1 pM Dex treated culture as judged by transferrin staining 
(Fig 6.1 A-E). Interestingly, we can even find transferrin positive cells in buds treated 
with 1 nM Dex (Fig 6.1 A). This is slightly different from the results I obtained in 
AR42J-B13 cells (Chapter 3).
The cultures were analysed for the expression of two genes-insulin and 
Pancreatic duodenal homeobox-1 (PDX-1, also known as insulin promoter factor-1 
(IPF-1)). In chapter 5 ,1 have shown that there is a large number of insulin expressing 
cells forming in control 7-day bud culture, and some of the cells start to form an islet­
like structure. Treatment with Dex caused the significant reduction of both insulin and 
PDX-1 expression (Fig 6.1F-0). If the effect of Dex persists, it might cause insulin 
deficiency in late life, which might lead to type II diabetes.
In order to analyse whether the effect can persist after removal of 
glucocorticoid from medium, I set up a time course experiment, and added 1 pM Dex 
to the buds at day 2, and cultured for five days, then removed Dex and cultured for a 
further 4 days. Representative fields are shown in Fig 6.2. The early expression of 
PDX1 is not much affected by the Dex, but the late expression is greatly reduced and 
remains low 4 days after Dex withdrawal. PDX-1 normally has two phase of
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expression: the early phase in the whole pancreatic bud region and the later phase in 
the (3 cells where it serves as a positive regulator of insulin transcription. The results 
shown here suggest that glucocorticoids reduce the insulin expression and that the 
effect may outlast the period of treatment.
After removal of Dex from culture for 4 days, we still can find some cells 
expressing transferrin (Fig 6.2 O). This result suggests the hepatic metaplasia is an 
irreversible process which is supported by observation in AR42J-B13 cells (see 
Chapter 3.8 ) There were some cells re-expressed insulin and PDX-1 (Fig 6.2 F, L), 
but either the organisation of pancreas or the ratio of cells has been altered by Dex 
treatment.
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Control Dex InM Dex lOnM Dex lOOnM Dex luM
Fig 6.1 Effect of different concentrations of Dex (0, 1,10,100,1000 nM) on pancreatic 
buds. Buds were cultured for 5 days without or with Dex, fixed and stained for 
transferrin (A-E), insulin (F-J) or PDX-1 (L-P)
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Day 4 (Dex 2d) Day 7 (Dex 5d) Day 11(- Dex 4d)
Fig 6.2 Time-course of insulin and PDX-1 expression with or without 1 jiM Dex. 
Buds were isolated from E11.5d mice embryo, and cultured for 2 days without 
treatment. Some buds were treated with 1 |iM Dex for 2 days (D, J, M), or 5days (E, 
K, N). For F, J and O, buds were treated with 1 pM Dex for 5 days, and then Dex was 
removed and cultures was maintained in control medium for a further 4 days. Cultures 
were fixed at day 4, day 7 and day 11, and stained for insulin (A-F), PDX-1 (G-L) or 
transferrin (M-O)
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6.4 Suppression of insulin via induction of C/EBPp
Glucocorticoids are diabetogenic hormones because they decrease glucose 
uptake and increase hepatic glucose production (Delaunay et al., 1997). In addition, 
they may directly inhibit insulin release. Glucocorticoid has been shown to inhibit 
insulin expression in cultured pancreatic islet cells (Femandez-Mejia et al., 1999; 
Seufert et al., 1998). Importantly, previous studies performed by Habener and 
colleagues identified the basic leucine zipper transcription factor C/EBPp as an 
inhibitor of insulin gene transcription in pancreatic beta cells and is also upregulated in 
animal models of diabetes mellitus. Concomitant with a downregulation of PDX-1 and 
insulin expression, C/EBPP is upregulated in association with the manifestation of 
hyperglycemia during the development of diabetes in the Zucker diabetic fatty (fa/fa) 
rat (Seufert et al., 1998). These findings suggest a role for glucocorticoids and 
C/EBPP the development of diabetes.
In previous chapters, we have shown that dexamethasone can induce C/EBPP 
which plays a key role in the formation of hepatic metaplasia in vitro and ex vivo. In 
this chapter, we also find the formation of hepatic metaplasia accompanied by the 
reduction of insulin expression in pancreatic buds. In order to determine whether 
induction of C/EBPp by dexamethasone is involved in the down-regulation of insulin, 
I decided to examine the response of RIN-5F cells. RIN-5F is a subclone drived from 
RIN-m cells, widely used pancreatic p-cell lines that can express and produce insulin. 
Here the results show that treatment of luM of Dexamethasone for 4 days is sufficient 
to suppress insulin and increase C/EBPp expression in RIN-5F cells (Fig 6.3A-C). 
After 6 days of Dex treatment, the expression of insulin was almost gone (Fig 6.4 C).
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When I pre-treated the cells with glucocorticoid inhibitor-RU486, the expression of 
C/EBPp was suppressed and the insulin expression maintained (Fig 6.3 D).
In order determine whether C/EBPp is a key gene in the reduction of insulin 
expression, I transfected LIP (the inactive form of C/EBPp) and LAP (the active form 
of C/EBPP) into RIN-5F cells. As expected, the transfection of LIP didn’t cause the 
reduction of insulin and the transfection of LAP was sufficient to inhibit the expression 
of insulin (Fig 6.5 B, C). These findings suggest the induction of C/EBPp by 
dexamethasone play the major role in suppression of insulin. Interestingly, the 




Control Dex lOnM Dex luM RU486 + Dex luM
Fig 6.3 Dexamethasone suppresses insulin and increases C/EBPp expression in RIN- 
5F cells. Cells were incubated with 10 nM or 1 |iM Dex for 4 days with or without the 
pretreatment of 2.5 pM RU486. Cells were dual-stained with (A)-(D) anti-insulin 








Fig 6.4 Time-course of insulin expression in RIN-5F cells treated with Dex.
RIN-5F cells were treated with 1 (iM Dex for 4days (B) and 6 days (C), and then fixed 
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Fig 6.5 Inhibition of expression of insulin by LAP
RIN-5F cells were transfected with CMV-nucGFP, CMV-LIP (inactive form of 
C/EBPp) and CMV-LAP (active form of C/EBPp). After 72 hrs of transfection, cells 
were fixed and dual-stained for (A) anti-insulin (Red) / anti-GFP (Green) antibodies 
(B)-(C) anti-insulin (Green) /  anti-C/EBPp (Red), (i.e. LIP or LAP can be detected by 
immunohistochemistry because the C/EBPP antibody is raised to the C-terminus. LIP 
or LAP transfected cells are intensely stained)
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6.5 Formation of abnormal islets in vivo
To study whether exposure of glucocorticoid in the late gestation can cause the alteration 
of pancreatic organisation and hepatic metaplsia in vivo, we obtained the glucocorticoid treated 
rats’ pancreas from Prof. J. R. Seckl. The procedure was performed as described previously 
(Nyirenda et al, 1998). Briefly, mothers were treated throughout the 3rd week of gestation 
(from day 15 to day 21-22 (depending on when pups were bom)), and then the offspring were 
sacrificed 3 weeks postnatally. Adult offspring have been shown to display hyperglycemia.
Here, we investigate the distribution of a- and p-cells in the islets via the presence of 
insulin and glucagon by immunohistochemistry. Glucagon-secreting a-cells are normally 
distributed around the periphery of the islet while the insulin-secreting P-cells represent the 
majority of the islet cells and fill its core (Fig 6.6A, B). In glucocorticoid treated animals, the 
distribution of a-cells was altered. Occasionally, glucagon-secreting a-cells can be found to 
penetrate deep into the islet (Fig 6.6C, E). In addition, there were fewer numbers of insulin 
positive cells in the islet, and staining for insulin was less intense (Fig 6.6 D, F) compared to 
control sample (Fig 6.6B). The results suggest a permanent reduction of P- cells mass occurred 
in these Dex treated rats which may cause imbalance of glucagon and insulin secretion..
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Fig 6.6 Glucagon or insulin in sections of pancreas from control rats (A, B) or rats treated with 
Dex during the late gestation (C-F). A, C, E glucagon staining; B, D, F insulin staining
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6.6 Formation of hepatocyte-like cells
Since the alteration of pancreatic organisation can be observed in the offspring 
of the glucocorticoid-treated dams which is similar to the result we obtained in copper- 
deficient rats (Tosh et al., 2002, Data not shown), I decided to examine whether 
pancreatic hepatocytes exist in the animals. We performed histological examination of 
H&E stained sections of pancreas from 5 animals. There were some eosinophilic 
staining cells in one animal which is a feature typical of hepatocytes (Fig 6.6C-E). In 
order to determine whether these cells are hepatocytes, the neighbouring sections were 
stained with transferrin and albumin antibodies. The result showed that these 
eosinophilic staining cells did indeed express transferrin and albumin (Fig 6.7). 
Normally, albumin also exists in the circulation system, so some blood vessels have 
been stained positive for in the control (Fig 6.8).
The finding of hepatocyte-like cells existed in these glucocorticoid treated 
animal supports our results in vitro and ex vivo. That is to say, glucocorticoids could 
possibly induce hepatic metaplasia in vivo. Unfortunately, like most in vivo 
experiments, it is very difficult to determine the origin of these hepatocyte-like cells, 
and we are so far unable to conclude the association of the hepatic metaplasia and 
developing glucose intolerance in this animal model.
126

Fig 6.7 Haemotoxylin and eosin staining of pancreases from either control rats (A-B) or treated 
with Dex during the late gestation (C-F). (C) show eosinophilic staining cells in the edge. (D, 
E) shows eosinophilic staining cells in lymphoid-like tissue within pancreas. (F) Some fat tissue 










Fig 6.8 Eosinophilic staining cells expressed transferrin. Sections from either rats treated with 
Dex during late gestation (A-I) or control rats (J-L) stained with anti-transferrin antibodies. (A, 
D) show eosinophilic staining cells in the edge expressed transferrin. (G) shows eosinophilic 
staining cells in lymphoid-like tissue also expressed transferrin.
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Alb Die Overlay
Fig 6.9 Eosinophilic staining cells expressed albumin. Sections from either rates treated with 
Dex during the late gestation (A-I) or control rats (J-L) were stained with anti-albumin 
antibodies. (A, D) show eosinophilic staining cells in the edge expressed albumin. (G) shows 
eosinophilic staining cells in lymphoid-like tissue also expressed albumin. (J) Blood vessels 
have been stained positive for albumin, which serve as a positive control.
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6.7 Discussion
We demonstrate in this chapter that the treatment with 1 nM Dex is sufficient 
to reduce insulin and PDX-1 expression in mouse embryo pancreatic buds. The results 
indicate that the fetal pancreas may be very sensitive to glucocorticoids, and it could 
be the reason why the fetus has much lower levels of physiological glucocorticoid than 
the adult. Recent evidence provided by Bre’ant and colleagues also supports our 
finding (Blondeau et al., 2001). They show that undemutrition significantly increased 
maternal and fetal corticosterone level. Twenty-one-day-old fetuses with 
undemutrition showed growth retardation and decreased pancreatic insulin content. 
What is more, adrenalectomy and subcutaneous corticosterone implants in their dams 
prevented the maternal corticosterone increase and restored fetal p-cell mass. Their 
data also suggest a negative role of glucocorticoids in fetal p-cell development.
Hattersley and Tooke made a “fetal insulin hypothesis” to explaine the 
association of low birthweight with diabetes and vascular disease (Hattersley and 
Tooke, 1999). They propose that genetically determined insulin resistance results in 
impaired insulin- mediated growth in the fetus as well as insulin resistance in adult 
life. There is evidence to support this hypothesis (Hill, 1976). Human disorders where 
excessive insulin secretion and beta cell hyperplasia are present result in fetal 
overgrowth. Experimental models confirm an important anabolic effect of insulin in 
utero. In contrast with this data is the evidence of intrauterine growth retardation 
occurring in association with insulinopenia or total absence of fetal insulin. Without 
the anabolic effect of insulin, no amount of substrate will induce optimal growth. It is 
evident from both the clinical and experimental data that sensitivity to insulin 
(probably individual receptor sites) develops in the latter stages of pregnancy.
130
Insulin secretion by the fetal pancreas in response to maternal glucose 
concentrations is a key growth factor. Monogenic diseases that impair sensing of 
glucose, lower insulin secretion, or increased insulin resistance are associated with 
impaired fetal growth. In this chapter, we found the exposure of fetal pancreas to 
glucocorticoid could significantly affect the formation of p cells, or the expression of 
insulin. And the reduction of fetal insulin plays a role to cause the fetal retardation.
PDX-1 is a homeodomain protein. In mouse embryos, PDX-1 expression is 
restricted to the developing pancreatic anlagen and is initiated when the foregut 
endoderm is committed to a pancreatic fate. Edlund and her colleagues showed that 
mice homozygous for a targeted mutation in the pdx-1 gene selectively lack a pancreas 
(Jonsson et al., 1994). The mutant pups survive fetal development but die within a few 
days after birth. The gastrointestinal part and all other internal organs were normal in 
appearance. No pancreatic tissue and no ectopic expression of insulin was detected in 
mutant embryos and neonates. These findings show that PDX-1 is needed for the 
formation of the pancreas and suggest that it acts to determine the fate of common 
pancreatic precursor cells and/or to regulate their propagation. In the adult mouse 
pancreas, PDX-1 is selectively expressed in the p-cells and binds to and transactivates 
the insulin promoter (Habener and Hussain 2001). p-cell specific inactivation of the 
mouse Ipfl/pdxl gene results in loss of the beta-cell phenotype and maturity onset 
diabetes (Ahlgren, 1998). Here, we also showed PDX-1 was down-regulated by 
glucocorticoid. Montminy and co-workers have performed experiments in HIT cells 
which showed that glucocorticoid can repress PDX-1 gene expression by interfering 
with HNF-3p activity on the islet-specific enhancer (Sharma et al., 1997). As a result, 
we believe reduction of PDX-1 in the late gestation by glucocorticoids could play a
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role to form the abnormal pancreas and develop diabetes in postnatal life.
In previous chapters, we have shown that dexamethasone can induce C/EBPP 
which plays a key role in the formation of hepatic metaplasia in vitro and ex vivo. 
Here, we also show that Dex can induce the expression of C/EBP |3 in RBM-5F cells. 
The transfection of LAP, the constitutively active form of C/EBPp is sufficient to 
suppress insulin expression. Previous studies performed by Habener and colleagues 
also show that after exposure to high glucose concertration, the p-cell line HIT-T15 
and INS-1 express high level of C/EBPp which directly binds to rat insulin I promoter 
and inhibits the transcription (Lu et al., 1998). The result also supports the idea that 
expression of C/EBPp can inhibit insulin expression.
Although there is no evidence to suggest that hepatic metaplasia plays a role in 
the development of type II diabetes, the liver plays a central role in the control of 
glucose homeostasis and is subject to complex regulation by substrates, insulin, and 
other hormones. Insulin resistance in the liver has been suggested to be a later factor in 
the development of hyperglycemia, with increased hepatic glucose production tightly 
correlated with fasting hyperglycemia in type 2 diabetic individuals (DeFronzo, 1997). 
Recent evidence provided by Kahn and colleagues has shown loss of direct insulin 
action in mice caused dramatic insulin resistance, severe glucose intolerance, and a 
failure of insulin to suppress hepatic glucose production and to regulate hepatic gene 
expression (Michael et al., 2000). Thus, the result suggests that insulin signalling in 
the liver is critical in regulating glucose homeostasis and maintaining normal hepatic 
function. In present studies, we show that glucocorticoid treatment reduces the 
expression of insulin during embryogenesis and/or in postnatal life. The defect in 
insulin signalling would probably disrupt the glucose homeostasis and cause abnormal
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hepatic function. What is more, the formation of pancreatic hepatocytes may also be 
involved. Although, in the present studies, we cannot provide the further evidence to 
support this hypothesis, it at least provides an additional view to uncover the 
mechanism which may cause type II diabetes in later life.
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CHAPTER 7
FINAL DISCUSSION AND FUTURE PROSPECTS
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Numerous examples of transdifferentiation exist but perhaps one of the most 
interesting is the appearance of hepatocytes in the pancreas. Foci of hepatocytes have 
been shown to be induced in the pancreas of rats, mice or hamsters following various 
experimental procedures. I demonstrate in the present study the ability of the synthetic 
glucocorticoid dexamethasone to induce the formation of hepatocytes from pancreatic 
cells. The fact that treatment of mouse embryo pancreatic buds also yields hepatocytes 
shows that this effect is not simply a tissue culture artifact but mimics a normal 
developmental switch.
In the AR42J-B13 cells, the addition of Dex induces morphological change. 
The cells begin to flatten onto the substratum within 48-72hrs. The morphological 
change is associated with the gain of expression of liver markers. B13 cells induced to 
undergo transdifferentiation to hepatocytes with Dex begin to express ai-antitrypsin, 
glucose-6-phosphatase (G6Pase), phenol sulphotransferase and transferrin. Later 
(around 7 days) the cells begin to express albumin. Embryonic pancreatic buds 
cultured with Dex also begin to express liver markers suggesting that the conversion of 
pancreatic cells to hepatocytes by glucocorticoid is physiologically relevant.
A variety of cell types have been proposed to give rise to hepatocytes including 
exocrine and endocrine cells as well as the pancreatic ductular system. Although 
several experimental models support the concept that cells capable of 
transdifferentiating to hepatocytes exist in the pancreas, there is no consensus as to 
which are the real progenitor cells. In order to distinguish where hepatocytes were 
derived from exocrine cells a lineage experiment was designed based on the 
perdurance of green fluorescent protein. The exocrine-specific elastase promoter was 
used to drive green fluorescent protein and transfected into B13 cells. This experiment
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clearly shows that GFP and liver markers can be detected in the same cell. It indicates 
some of hepatocytes must have arisen from cells which had an active elastase promoter 
(differentiated exocrine cells). Such a direct conversion between one differentiated 
cell type (exocrine cell) and another (hepatocyte) is a true transdifferentiation event.
The conversion of pancreatic cells to hepatocytes provides the novel 
opportunity to study the molecular basis of transdifferentiation and perhaps identify 
the master switch gene for pancreas to liver in the process. To understand the 
molecular basis of the switch several approaches have been taken. AR42J-B13 cells 
were examined for the expression of various liver-enriched transcription factors and it 
is apparent that those examined are already expressed in the pancreatic cell line. In the 
normal pancreas, many of the LETFs are also already expressed albeit in different cell 
types. However, C/EBPp was not normally expressed in B13 cells but is induced 
shortly after Dex-treatment. When C/EBPp was transfected into B13 cells, the 
expression of amylase was reduced and some liver markers were expressed suggesting 
that this transcription factor is important in the conversion of pancreatic cells to 
hepatocytes. To test this further, when the dominant negative form of C/EBPp (termed 
liver inhibitory protein or LIP) was transfected into B13 pancreatic cells 
transdifferentiation was inhibited. This evidence suggests that C/EBPp may indeed be 
the master switch gene for the liver to pancreas transdifferentiation.
Low birth weight is an important risk factor for type II diabetes in later life. In 
the present studies, I also show that glucocorticoids can both abnormal cause 
pancreatic development and hepatic metaplasia. Significant reduction of insulin 
expression was observed in Dex treated pancreatic buds, RIN-5F cells and in the 
pancreas of rat offspring. Pancreatic hepatocytes were also found in Dex treated 
pancreatic buds and one example of a pancreas exposed to Dex in utero. The evidence
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suggests glucocorticoid not only can induce hepatic metaplasia, but it might also play a 
negative role in regulating fetal growth and pancreatic development.
As AR42J-B13 cells resemble a pluripotent pancreatic cell, so precursor cells 
might exist. In this study, I cannot provide sufficient evidence to exclude the 
possibility. Although we do show that at least some of the hepatocytes are formed 
directly from exocrine-like cells with no intervening cell division, we cannot ignore 
the possibility that hepatocytes arises from stem cells. Recent evidence show that 
tissue-specific stem cells can give rise to cells of heterologous lineages (Goodell 
2001). For example, hepatocytes can differentiate from hematopoietic stem cell 
populations. Recent evidences also show that tissue-specific stem cells can give rise 
to cells of heterologous lineages (Goodell 2001). For example, hepatocytes can 
differentiate from hematopoietic stem cell populations. Recent lineage-marking 
studies of mice after bone marrow transplantation have challenged the view that 
hepatocytes must be derived from the endoderm or endoderm-derived cells (Petersen 
et al., 1999; Alison et al., 2000 Lagasse et al., 2000). Although the interpretation of 
these experiments require re-examination in light of other recent experiments (Ying et 
al., 2002; Terada et al., 2002), it remains important to establish whether there exists a 
common stem cell for liver and pancreas, and whether there are pathways of 
transdifferentiation in addition to that established so far.
Although some of the details of the transdifferentiation of pancreas to liver 
have now been established, some questions still remain to be answered. In particular, 
the role of C/EBPp (and other members of the C/EBP family) in normal liver 
development is poorly understood. For example, the expression patterns of C/EBPs 
shall be determined during embryonic development. It is also necessary to determine
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whether hepatocytes can arise from other pancreatic cell types apart from exocrine 
cells and whether the transdifferentiation of exocrine cells to hepatocytes has any real 
significance to the situation in humans.
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